

Financial Statements

Contents

Independent Auditors' Report	172
Consolidated Income Statement	182
Consolidated Statement of Comprehensive Income	183
Consolidated Statement of Financial Position	184
Consolidated Statement of Changes in Shareholders' Equity	185
Consolidated Statement of Cash Flows	186
Notes to the Consolidated Financial Statements	187
Company Statement of Financial Position	235
Company Statement of Changes in Shareholders' Equity	236
Notes to the Company Financial Statements	237
Financial History	247

The Veterinary Perspective



Read more about us at:
www.dechra.com



Independent Auditors' Report to the Members of Dechra Pharmaceuticals PLC

Report on the audit of the financial statements

Opinion

In our opinion:

- Dechra Pharmaceuticals PLC's Group financial statements and Company financial statements (the "financial statements") give a true and fair view of the state of the Group's and of the Company's affairs as at 30 June 2023 and of the Group's loss and the Group's cash flows for the year then ended;
- the Group financial statements have been properly prepared in accordance with UK-adopted international accounting standards as applied in accordance with the provisions of the Companies Act 2006;
- the Company financial statements have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, including FRS 101 "Reduced Disclosure Framework", and applicable law); and
- the financial statements have been prepared in accordance with the requirements of the Companies Act 2006.

We have audited the financial statements, included within the Annual Report and Accounts (the "Annual Report"), which comprise: the Consolidated and Company Statements of Financial Position as at 30 June 2023; the Consolidated Income Statement and Consolidated Statement of Comprehensive Income, the Consolidated Statement of Cash Flows, and the Consolidated and Company Statements of Changes in Shareholders' Equity for the year then ended; and the notes to the financial statements, which include a description of the significant accounting policies.

Our opinion is consistent with our reporting to the Audit Committee.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) ("ISAs (UK)") and applicable law. Our responsibilities under ISAs (UK) are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We remained independent of the Group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, which includes the FRC's Ethical Standard, as applicable to listed public interest entities, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

To the best of our knowledge and belief, we declare that non-audit services prohibited by the FRC's Ethical Standard were not provided.

Other than those disclosed in the Audit, Risk and Internal Control Report, we have provided no non-audit services to the Company or its controlled undertakings in the period under audit.

Material uncertainty related to going concern

In forming our opinion on the financial statements, which is not modified, we have considered the adequacy of the disclosure made in note 1(b) to the financial statements concerning the Group's and the Company's ability to continue as a going concern. On 20 July 2023 Dechra Shareholders approved the recommended cash acquisition by Freya Bidco Limited of the entire issued, and to be issued, ordinary share capital of Dechra. The acquisition is expected to complete in late 2023, after the date of approval of the Annual Report and Accounts. The going concern assessment of the Company and Group is therefore subject to uncertainties relating to the potential change in ownership of the Group and the actual funding requirements and financing arrangements post completion. For this reason, the Directors cannot reasonably predict the financial position of the Group post-completion, including the details of any financing arrangements related to the transaction that could affect the Group. These conditions, along with the other matters explained in note 1(b) to the financial statements, indicate the existence of a material uncertainty which may cast significant doubt about the Group's and the Company's ability to continue as a going concern. The financial statements do not include the adjustments that would result if the Group and the Company were unable to continue as a going concern.

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Our evaluation of the directors' assessment of the Group's and the Company's ability to continue to adopt the going concern basis of accounting included:

- Evaluating management's detailed cash flow forecasts and both liquidity and covenant headroom under both base case and downside scenarios.
- Comparison of the going concern base case forecasts to Board approved forecasts and where applicable, we compared these forecasts for consistency to those used elsewhere in the business, including for impairment assessments. We also considered whether they were reasonable in light of previous performance, future expectations and management's track record of accurate forecasting.
- Reading the key terms of all committed debt facilities to understand any terms, covenants or undertakings that may impact the availability of the facility.
- Assessing the performance against debt covenants under both the base case and downside scenarios.
- Assessing the adequacy of disclosures in the going concern statement on page 187 and statement in note 1(b) of the financial statements.

In relation to the directors' reporting on how they have applied the UK Corporate Governance Code, other than the material uncertainty identified in note 1(b) to the financial statements, we have nothing material to add or draw attention to in relation to the directors' statement in the financial statements about whether the directors considered it appropriate to adopt the going concern basis of accounting, or in respect of the directors' identification in the financial statements of any other material uncertainties to the Group's and the Company's ability to continue to do so over a period of at least twelve months from the date of approval of the financial statements.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Our Audit Approach

Overview

Audit scope

- Following our assessment of the risks of material misstatement of the Group financial statements we performed audits of the complete financial information of 16 reporting units.
- As well as auditing the Company, the Group engagement team audited the Company and certain centralised functions, including those covering Group treasury operations, corporate taxation, goodwill and intangible asset impairment assessments and licensing agreements and their associated contingent consideration balances.
- The components on which audits of the complete financial information and centralised work were performed accounted for 83% of Group revenue, 80% of Group underlying operating profit and 85% of Group loss before tax. In addition, two component teams were instructed to perform specified procedures over two reporting units, and a further component team was instructed to perform specified procedures over elements of the opening balance sheet for one component acquired during the year.
- We issued formal written instructions to all component auditors setting out the audit work to be performed by each of them and maintained regular communication with the component auditors throughout the audit cycle. These interactions included attending certain component clearance meetings and holding regular conference calls, as well as reviewing and assessing any matters reported. The Group engagement team also reviewed selected audit working papers for certain component teams to evaluate the sufficiency of audit evidence obtained and fully understand the matters arising from the component audits. In addition, the Group engagement team visited two overseas locations. The Group engagement team also audited all of the UK components that were in scope for the Group audit.

Key audit matters

- Material uncertainty related to going concern
- Licensing agreements and associated contingent considerations (Group and Company)
- Impairment of in-process research and development (IPR&D) (Group)
- Business combinations - valuation of intangible assets (Group)
- Carrying value of the Company's investments (Company)

Materiality

- Overall Group materiality: £4.95 million (2022: £5.22 million) based on 3% of underlying operating profit.
- Overall Company materiality: £4.1 million (2022: £3.2 million) based on 0.5% of net assets.
- Performance materiality: £3.7 million (2022: £3.9 million) (Group) and £3.1 million (2022: £2.4 million) (Company).

Independent Auditors' Report to the Members of Dechra Pharmaceuticals PLC

The scope of our audit

As part of designing our audit, we determined materiality and assessed the risks of material misstatement in the financial statements.

Key audit matters

Key audit matters are those matters that, in the auditors' professional judgement, were of most significance in the audit of the financial statements of the current period and include the most significant assessed risks of material misstatement (whether or not due to fraud) identified by the auditors, including those which had the greatest effect on: the overall audit strategy; the allocation of resources in the audit; and directing the efforts of the engagement team. These matters, and any comments we make on the results of our procedures thereon, were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

In addition to going concern, described in the Material uncertainty related to going concern section above, we determined the matters described below to be the key audit matters to be communicated in our report. This is not a complete list of all risks identified by our audit.

The valuation of intangible assets acquired through business combinations is a new key audit matter this year. Otherwise, the key audit matters below are consistent with last year.

Key audit matter	How our audit addressed the key audit matter
Licensing agreements and associated contingent considerations (Group)	
Refer to the Audit, Risk and Internal Control Report, note 1(b) to the consolidated financial statements (Key sources of estimation uncertainty) and note 30 (Contingent Consideration Liabilities).	In respect of the remeasurement of contingent consideration: We obtained management's model and reperformed the calculation of the contingent consideration; We obtained evidence to evaluate the key assumptions underpinning management's cash flow forecasts, including considering the existence of contradictory evidence, and benchmarked longer term growth rates against external market data;
During the year, liabilities in respect of all existing licensing agreements, the largest being Laverdia and Tri-Solfen, were reassessed based on the most recent forecast of the timing and quantum of future cash flows. The discount rate applied was also reassessed. The variability of the timing and quantum of future cash flows and the discount rate to be applied represent an area of estimation uncertainty.	Our valuation experts evaluated the discount rates used by management against our experts' own independent expectations, which included consideration of other companies in the industry of comparable size and geographical spread; and
The accounting for contingent consideration involves estimation uncertainty over the timing and quantum of future cash flows and the discount rate to be used.	We audited the disclosures relating to licensing agreements and contingent consideration to ensure these were consistent with the requirements of the applicable standards. Overall we found the accounting for licensing agreements and associated contingent consideration, and the related disclosures, to be consistent with the audit evidence obtained.

Key audit matter	How our audit addressed the key audit matter
Impairment of in-process research and development (IPR&D) (Group)	
<p>Refer to the Audit, Risk and Internal Control Report, note 1(b) to the consolidated financial statements (Key sources of estimation uncertainty) and note 14 (Impairment Reviews).</p> <p>The Group recognised £173.4m of IPR&D on acquisition of Piedmont Animal Health Inc. IAS 36 requires entities to annually test for impairment any intangible assets not yet available for use.</p> <p>As such, management have reviewed each of the Piedmont products acquired for impairment.</p> <p>This has resulted in management recognising an impairment of £69.1m in relation to one product, driven by a reduction of the estimated probability of success of the product.</p> <p>There is significant complexity and estimation uncertainty associated with the assumptions made in the impairment review of IPR&D assets.</p>	<p>In respect of the IPR&D impairment assessment:</p> <ul style="list-style-type: none"> • We considered management’s determination of the cash generating units for assessing impairment, being the individual product level; • We audited management’s model and reperformed the calculations within the discounted cash flow forecasts; • We corroborated key assumptions back to those tested as part of our audit of acquisition accounting, and challenged management on assumptions that had, or had not, changed; • We reviewed correspondence from the FDA; • We held discussions with Dechra’s internal experts including the Chief Scientific Officer; • We used our valuation experts to evaluate the discount rate assumptions; • We performed sensitivity analysis on management’s model in order to identify key assumptions by assessing whether reasonable changes could result in a material error; and • We audited the disclosures associated with the impairment review <p>Overall, we found the assessment of the carrying value of IPR&D and associated disclosures to be consistent with the evidence obtained.</p>

Independent Auditors' Report to the Members of Dechra Pharmaceuticals PLC

Key audit matter

How our audit addressed the key audit matter

Business combinations - valuation of intangible assets (Group)

Refer to the Audit, Risk and Internal Control Report, note 1(b) to the consolidated financial statements (Key sources of estimation uncertainty) and note 29 (Acquisitions).

During the year the Group undertook two corporate acquisitions, Med-Pharmex Holdings Inc, and Piedmont Animal Health Inc. As a result of meeting the definition of a business combination the Group are required to apply the principles of IFRS 3 and to identify and value the identifiable assets and assumed liabilities.

The Group recognised £173.4m of intangible assets on the acquisition of Piedmont Animal Health Inc, relating entirely to IPR&D. The Group recognised £137.6m of intangible assets on the acquisition of Med-Pharmex Holdings Inc, relating largely (£134.9m) to six developed products.

There is significant complexity and estimation uncertainty associated with the assumptions made in the fair value measurement exercise for intangible assets.

In respect of Med-Pharmex Holdings Inc.:

- We audited management's model and reperformed the calculations within the discounted cash flow forecasts;
- We performed sensitivity analysis on management's model in order to identify key assumptions by assessing whether reasonable changes could result in a material error;
- We obtained evidence to evaluate the key assumptions underpinning management's cash flow forecasts, including considering the existence of contradictory evidence;
- We held discussions with Dechra's internal commercial and veterinary experts to understand the planned strategy for the products and expected impact on assumptions taken in the cash flow forecasts;
- Our valuation experts assessed the appropriateness of the methodology used in the models and also certain economically driven assumptions such as discount rates and long-term growth rates; and
- We audited the disclosures relating to business combinations to ensure these were consistent with the requirements of the applicable standards.

In respect of Piedmont Animal Health Inc:

- We audited management's model and reperformed the calculations within the discounted cash flow forecasts;
- We performed sensitivity analysis on management's model in order to identify key assumptions by assessing whether reasonable changes could result in a material error;
- We obtained evidence to evaluate the key assumptions underpinning management's cash flow forecasts, including considering the existence of contradictory evidence;
- We reviewed regulatory correspondence and held discussions with the Product Development and Regulatory Affairs department, to assess whether the information used by management was complete and accurate;
- Our valuation experts assessed the appropriateness of the methodology used in the models and also certain economically driven assumptions such as discount rates and long-term growth rates; and
- We audited the disclosures relating to business combinations to ensure these were consistent with the requirements of the applicable standards.

Overall, we found the accounting for intangible assets acquired through business combinations, and the related disclosures, to be consistent with the audit evidence obtained.

Key audit matter	How our audit addressed the key audit matter
Carrying value of the Company's investments (Company)	
Refer to note (i) to the Company financial statements and note (iv) (Investments).	We audited the distribution of the 14% stake in Dechra Finance Limited from Dechra Finance Sterling Limited to the Company.
Investments in subsidiaries of £920.1 million (2022: £735.7 million) are accounted for in the Company balance sheet at cost less provision for impairment.	We audited the share capital reduction in Dechra Finance Limited and the dividend payment to the Company.
Investments are tested for impairment if impairment indicators exist. If such indicators exist, the recoverable amounts of the investments in subsidiaries are estimated in order to determine the extent of the impairment loss, if any. Any such impairment loss is recognised in the income statement.	We evaluated management's determination of whether there were any other indicators of impairment. Our procedures, in addition to the above, included:
A review for indicators of impairment was performed by management, including considering the latest available forecasts and developments in the Group during the year.	<ul style="list-style-type: none"> • We compared the carrying value of investments with the market capitalisation of the Group at 30 June 2023; • We compared the carrying value of investment with the carrying amount of investees' net assets; • We audited management's calculation of the recoverable amount of the investments in Dechra Finance Limited and Dechra Finance Sterling Limited; and • We audited the disclosure note associated with the impairment review. Overall we found the assessment of the carrying value of the Company's investments and associated disclosures to be consistent with the evidence obtained.
In March 2023, Dechra Finance Sterling Limited distributed its 14% stake in Dechra Finance Limited to the Company, taking the Company's total shareholding in Dechra Finance Limited to 100%. Following the distribution, the Company's investment in Dechra Finance Sterling Limited was considered for impairment and no impairment was identified.	
In March 2023, Dechra Finance Limited reduced its share capital and paid a dividend equivalent to the amount of the capital reduction to the Company. In addition, as a result of the unwinding of an internal Group financing arrangement, certain loan receivables and payables of an equal amount were settled and going forward Dechra Finance Limited's future net interest cash inflow will be less.	
As a consequence, the Company's investment in the entity was tested for impairment. Management's assessment identified an impairment of £18.9 million.	

How we tailored the audit scope

We tailored the scope of our audit to ensure that we performed enough work to be able to give an opinion on the financial statements as a whole, taking into account the structure of the Group and the Company, the accounting processes and controls, and the industry in which they operate.

The Group is structured with three reportable segments, with each segment set up to manage operations on both a regional and functional basis and made up of a number of individual reporting units.

The Group financial statements are a consolidation of 50 active reporting units comprising the Group's operating businesses and centralised functions. These reporting units maintain their own accounting records and controls and report to the head office finance team in the UK.

We identified 16 of the Group's 50 active reporting units which, in our view, required a full audit of their complete financial information in order to ensure that sufficient audit evidence was obtained. The reporting units on which a full audit of their complete financial information was performed accounted for 83% of Group revenue, 80% of underlying operating profit and 85% of loss before tax. Of these reporting units, one was considered to be a significant components due to its financial significance. In addition, we instructed two component audit teams to perform specified procedures on two reporting units.

The Group consolidation, financial statements disclosures and a number of centralised functions were audited by the Group engagement team at the head office. These areas of the audit included, but were not limited to, central procedures on treasury operations, UK and corporate taxation and goodwill and intangible asset impairment assessments. We also performed Group level analytical procedures on all of the remaining out of scope active reporting units to identify any unusual transactions. The Company was also subject to a full scope audit.

Where work was performed by component auditors, we determined the level of involvement we needed to have in the audit work at those reporting units to be able to conclude whether sufficient appropriate audit evidence had been obtained as a basis for our opinion on the Consolidated Financial Statements.

Independent Auditors' Report to the Members of Dechra Pharmaceuticals PLC

We issued formal written instructions to all component auditors setting out the audit work to be performed by each of them and maintained regular communication with the component auditors throughout the audit cycle. These interactions included attending certain component clearance meetings and holding regular conference calls, as well as reviewing and assessing any matters reported. The Group engagement team also reviewed selected audit working papers for certain component teams to evaluate the sufficiency of audit evidence obtained and fully understand the matters arising from the component audits.

In addition, senior members of the Group engagement team visited two overseas locations.

The impact of climate risk on our audit

In planning and executing our audit, we also considered the potential impact of climate change on the Group's business and the financial statements. The Group has set out its intention, as part of the 'Making a Difference' plan, to achieve science-based net-zero greenhouse gas emissions ('GHG') for Scopes 1, 2 and 3 by no later than 2050. The Group has also submitted near term targets for Scopes 1, 2 and 3 to the Science Based Targets initiative (SBTi) for validation, using 2021 as a base year.

As a part of our audit we made enquiries of management to understand the extent of the potential impact of the physical and transitional climate change risk on the financial statements. We also discussed the climate change initiatives and commitments from the Making a Difference plan to reduce CO2 emissions, and the impact these have on the Group including on future cash flow forecasts.

Management considers that the impact of climate change does not give rise to a material financial statement impact. We evaluated management's risk assessment and understood the Group's governance processes, including the Sustainability Committee. We reviewed relevant Board and Audit Committee papers related to climate change and performed a risk assessment of how the impact of the Group's commitments in respect of climate change including the Making a Difference plan may affect the financial statements and our audit.

Using our knowledge of the Group, we assessed that the key areas in the financial statements which are more likely to be materially impacted by climate change are those areas that are based on future cash flows. As a result, we particularly considered how climate change risks and the impact of climate commitments made by the Group would impact the assumptions made in the forecasts prepared by management that are used in the Group's impairment reviews, for going concern purposes and for the valuation of intangible assets and related contingent consideration liabilities.

Based on our procedures, we have not identified any material error in the assessment of the impact of climate on the financial statements.

Materiality

The scope of our audit was influenced by our application of materiality. We set certain quantitative thresholds for materiality. These, together with qualitative considerations, helped us to determine the scope of our audit and the nature, timing and extent of our audit procedures on the individual financial statement line items and disclosures and in evaluating the effect of misstatements, both individually and in aggregate on the financial statements as a whole.

Based on our professional judgement, we determined materiality for the financial statements as a whole as follows:

	Financial statements – Group	Financial statements – Company
Overall materiality	£4.95 million (2022: £5.22 million).	£4.1 million (2022: £3.2 million).
How we determined it	3% of underlying operating profit	0.5% of net assets
Rationale for benchmark applied	We believe the Group's principal measure of performance and earnings is underlying operating profit. Management uses this measure as it believes that it eliminates material non-operational items that may obscure the key trends and factors in determining the Group's operational performance. Furthermore it is this measure which represents the primary focus for management and key stakeholders.	The Company is the ultimate holding Company of the Dechra Group of companies. As the Company has no trading activity, net assets is considered to be the primary measure used by the shareholders in assessing the performance of the entity, and is a generally accepted auditing benchmark.

For each component in the scope of our Group audit, we allocated a materiality that is less than our overall Group materiality. The range of materiality allocated across components was between £0.6 million and £4.5 million. Certain components were audited to a local statutory audit materiality that was also less than our overall Group materiality.

We use performance materiality to reduce to an appropriately low level the probability that the aggregate of uncorrected and undetected misstatements exceeds overall materiality. Specifically, we use performance materiality in determining the scope of our audit and the nature and extent of our testing of account balances, classes of transactions and disclosures, for example in determining sample sizes. Our performance materiality was 75% (2022: 75%) of overall materiality, amounting to £3.7 million (2022: £3.9 million) for the Group financial statements and £3.1 million (2022: £2.4 million) for the Company financial statements.

In determining the performance materiality, we considered a number of factors – the history of misstatements, risk assessment and aggregation risk and the effectiveness of controls – and concluded that an amount at the upper end of our normal range was appropriate.

We agreed with the Audit Committee that we would report to them misstatements identified during our audit above £0.25 million (Group audit) (2022: £0.25 million) and £0.20 million (Company audit) (2022: £0.16 million) as well as misstatements below those amounts that, in our view, warranted reporting for qualitative reasons.

Reporting on other information

The other information comprises all of the information in the Annual Report other than the financial statements and our auditors' report thereon. The directors are responsible for the other information, which includes reporting based on the Task Force on Climate-related Financial Disclosures (TCFD) recommendations. Our opinion on the financial statements does not cover the other information and, accordingly, we do not express an audit opinion or, except to the extent otherwise explicitly stated in this report, any form of assurance thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify an apparent material inconsistency or material misstatement, we are required to perform procedures to conclude whether there is a material misstatement of the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report based on these responsibilities.

With respect to the Strategic Report and Directors' Report – Other Disclosures ('Strategic Report and Directors' Report'), we also considered whether the disclosures required by the UK Companies Act 2006 have been included.

Based on our work undertaken in the course of the audit, the Companies Act 2006 requires us also to report certain opinions and matters as described below.

Strategic Report and Directors' Report

In our opinion, based on the work undertaken in the course of the audit, the information given in the Strategic Report and Directors' Report for the year ended 30 June 2023 is consistent with the financial statements and has been prepared in accordance with applicable legal requirements.

In light of the knowledge and understanding of the Group and Company and their environment obtained in the course of the audit, we did not identify any material misstatements in the Strategic Report and Directors' Report.

Directors' Remuneration

In our opinion, the part of the Directors' Remuneration Report to be audited has been properly prepared in accordance with the Companies Act 2006.

Corporate governance statement

The Listing Rules require us to review the directors' statements in relation to going concern, longer-term viability and that part of the corporate governance statement relating to the Company's compliance with the provisions of the UK Corporate Governance Code specified for our review. Our additional responsibilities with respect to the corporate governance statement as other information are described in the Reporting on other information section of this report.

Based on the work undertaken as part of our audit, we have concluded that each of the following elements of the corporate governance statement, included within the Governance section is materially consistent with the financial statements and our knowledge obtained during the audit, and, except for the matters reported in the section headed 'Material uncertainty related to going concern', we have nothing material to add or draw attention to in relation to:

- The directors' confirmation that they have carried out a robust assessment of the emerging and principal risks;
- The disclosures in the Annual Report that describe those principal risks, what procedures are in place to identify emerging risks and an explanation of how these are being managed or mitigated;
- The directors' statement in the financial statements about whether they considered it appropriate to adopt the going concern basis of accounting in preparing them, and their identification of any material uncertainties to the Group's and Company's ability to continue to do so over a period of at least twelve months from the date of approval of the financial statements;
- The directors' explanation as to their assessment of the Group's and Company's prospects, the period this assessment covers and why the period is appropriate; and
- The directors' statement as to whether they have a reasonable expectation that the Company will be able to continue in operation and meet its liabilities as they fall due over the period of its assessment, including any related disclosures drawing attention to any necessary qualifications or assumptions.

Independent Auditors' Report to the Members of Dechra Pharmaceuticals PLC

Our review of the directors' statement regarding the longer-term viability of the Group and Company was substantially less in scope than an audit and only consisted of making inquiries and considering the directors' process supporting their statement; checking that the statement is in alignment with the relevant provisions of the UK Corporate Governance Code; and considering whether the statement is consistent with the financial statements and our knowledge and understanding of the Group and Company and their environment obtained in the course of the audit.

In addition, based on the work undertaken as part of our audit, we have concluded that each of the following elements of the corporate governance statement is materially consistent with the financial statements and our knowledge obtained during the audit:

- The directors' statement that they consider the Annual Report, taken as a whole, is fair, balanced and understandable, and provides the information necessary for the members to assess the Group's and Company's position, performance, business model and strategy;
- The section of the Annual Report that describes the review of effectiveness of risk management and internal control systems; and
- The section of the Annual Report describing the work of the Audit Committee.

We have nothing to report in respect of our responsibility to report when the directors' statement relating to the Company's compliance with the Code does not properly disclose a departure from a relevant provision of the Code specified under the Listing Rules for review by the auditors.

Responsibilities for the financial statements and the audit

Responsibilities of the Directors for the financial statements

As explained more fully in the Statement of Directors' Responsibilities, the directors are responsible for the preparation of the financial statements in accordance with the applicable framework and for being satisfied that they give a true and fair view. The directors are also responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the Group's and the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or the Company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Based on our understanding of the Group and industry, we identified that the principal risks of non-compliance with laws and regulations related to the UK Corporate Governance Code, the Listing Rules and other regulations specific to the industries in which the Group operates (including those set by the Veterinary Medicines Directorate, European Medicines Agency and U.S. Food and Drug Administration), and we considered the extent to which non-compliance might have a material effect on the financial statements. We also considered those laws and regulations that have a direct impact on the financial statements such as the Companies Act 2006 and Tax legislation. We evaluated management's incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls), and determined that the principal risks were related to posting inappropriate journal entries to increase revenue or reduce expenditure to manipulate the financial performance of the business, and management bias in accounting estimates. The Group engagement team shared this risk assessment with the component auditors so that they could include appropriate audit procedures in response to such risks in their work. Audit procedures performed by the Group engagement team and/or component auditors included:

- Discussions with management, internal audit and the Group's legal counsel, including consideration of known or suspected instances of non-compliance with laws and regulation and fraud;
- Review of internal audit reports;
- Reading key correspondence with regulatory authorities, such as the Veterinary Medicines Directorate and U.S. Food and Drug Administration;
- Enquiries with component auditors;

- Identifying and testing unusual journal entries which increase revenue or reduce expenditure to manipulate the financial performance of the business; and
- Assessing key judgements and estimates made by management for evidence of inappropriate bias, in particular respect of the key audit matters noted above. Details of our procedures in these areas are included in our key audit matters above.

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

Our audit testing might include testing complete populations of certain transactions and balances, possibly using data auditing techniques. However, it typically involves selecting a limited number of items for testing, rather than testing complete populations. We will often seek to target particular items for testing based on their size or risk characteristics. In other cases, we will use audit sampling to enable us to draw a conclusion about the population from which the sample is selected.

A further description of our responsibilities for the audit of the financial statements is located on the FRC's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditors' report.

Use of this report

This report, including the opinions, has been prepared for and only for the Company's members as a body in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and for no other purpose. We do not, in giving these opinions, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.

Other required reporting

Companies Act 2006 exception reporting

Under the Companies Act 2006 we are required to report to you if, in our opinion:

- we have not obtained all the information and explanations we require for our audit; or
- adequate accounting records have not been kept by the Company, or returns adequate for our audit have not been received from branches not visited by us; or
- certain disclosures of directors' remuneration specified by law are not made; or
- the Company financial statements and the part of the Directors' Remuneration Report to be audited are not in agreement with the accounting records and returns.

We have no exceptions to report arising from this responsibility.

Appointment

Following the recommendation of the Audit Committee, we were appointed by the directors on 23 October 2015 to audit the financial statements for the year ended 30 June 2016 and subsequent financial periods. The period of total uninterrupted engagement is eight years, covering the years ended 30 June 2016 to 30 June 2023.

Other matter

As required by the Financial Conduct Authority Disclosure Guidance and Transparency Rule 4.1.14R, these financial statements form part of the ESEF-prepared annual financial report filed on the National Storage Mechanism of the Financial Conduct Authority in accordance with the ESEF Regulatory Technical Standard ('ESEF RTS'). This auditors' report provides no assurance over whether the annual financial report has been prepared using the single electronic format specified in the ESEF RTS.

Mark Skedgel (Senior Statutory Auditor)

for and on behalf of PricewaterhouseCoopers LLP
Chartered Accountants and Statutory Auditors
Birmingham

12 October 2023

Consolidated Income Statement

For the year ended 30 June 2023

	Note	2023			2022		
		Underlying £m	Non- underlying* (notes 3, 4 & 5) £m	Total £m	Underlying £m	Non- underlying* (notes 3, 4 & 5) £m	Total £m
Revenue	2	761.5	-	761.5	681.8	-	681.8
Cost of sales		(331.9)	(3.3)	(335.2)	(296.5)	(0.5)	(297.0)
Gross profit		429.6	(3.3)	426.3	385.3	(0.5)	384.8
Selling, general and administrative expenses		(207.0)	(152.2)	(359.2)	(178.6)	(74.6)	(253.2)
Research and development expenses		(57.5)	(3.3)	(60.8)	(32.4)	(3.7)	(36.1)
Operating profit/(loss)	2	165.1	(158.8)	6.3	174.3	(78.8)	95.5
Finance income	3	0.8	3.7	4.5	5.7	-	5.7
Finance expense	4	(24.6)	(21.4)	(46.0)	(8.8)	(13.5)	(22.3)
Share of (loss)/profit of investments accounted for using the equity method	6	(1.0)	0.1	(0.9)	(1.2)	(0.1)	(1.3)
Profit/(loss) before taxation	7	140.3	(176.4)	(36.1)	170.0	(92.4)	77.6
Income taxes	9	(32.4)	40.6	8.2	(38.3)	18.9	(19.4)
Profit/(loss) for the year		107.9	(135.8)	(27.9)	131.7	(73.5)	58.2
Earnings per share							
Basic	11			(24.59)p			53.72p
Diluted	11			(24.59)p			53.40p
Dividend per share	10			12.50p			44.89p

* The Group presents a number of non-GAAP Alternative Performance Measures (APMs). This allows investors to understand better the underlying performance of the Group, by excluding non-underlying items as set out in note 5.

Consolidated Statement of Comprehensive Income

For the year ended 30 June 2023

	Note	2023 £m	2022 £m
(Loss)/profit for the year		(27.9)	58.2
Other comprehensive (expense)/income:			
Items that may be reclassified subsequently to profit or loss:			
Foreign currency cash flow hedges			
– fair value movements		(2.0)	–
Foreign currency translation differences for foreign operations		(15.0)	15.7
Income tax relating to components of other comprehensive expense	9	(1.1)	(0.4)
		(18.1)	15.3
Total comprehensive (expense)/income for the year		(46.0)	73.5

Consolidated Statement of Financial Position

As 30 June 2023

	Note	2023 £m	2022 £m
Assets			
Non-current assets			
Intangible assets	12	922.4	730.5
Property, plant and equipment	13	159.3	100.3
Investments	6	14.9	15.8
Deferred tax assets	15	4.9	2.3
Total non-current assets		1,101.5	848.9
Current assets			
Inventories	16	217.3	175.7
Corporation tax receivable	20	14.3	11.0
Trade and other receivables	17	161.9	136.8
Cash and cash equivalents	18	74.4	120.9
Total current assets		467.9	444.4
Total assets		1,569.4	1,293.3
Liabilities			
Current liabilities			
Borrowings and lease liabilities	21	(3.9)	(3.3)
Trade and other payables	19	(144.5)	(136.8)
Contingent consideration	30	(4.1)	(6.4)
Corporation tax payable	20	(11.5)	(12.2)
Total current liabilities		(164.0)	(158.7)
Non-current liabilities			
Borrowings and lease liabilities	21	(500.6)	(325.8)
Contingent consideration	30	(71.6)	(104.0)
Provisions	22	(1.7)	(2.2)
Deferred tax liabilities	15	(76.3)	(35.8)
Total non-current liabilities		(650.2)	(467.8)
Total liabilities		(814.2)	(626.5)
Net assets		755.2	666.8
Equity			
Issued share capital	25	1.1	1.1
Share premium account		596.0	413.9
Own shares		(0.2)	–
Hedging reserve		–	–
Foreign currency translation reserve		(12.7)	3.4
Merger reserve		84.4	84.4
Retained earnings		86.6	164.0
Total equity		755.2	666.8

The financial statements on pages 182 to 247 were approved by the Board of Directors on 12 October 2023 and were signed on its behalf by:

Ian Page

Chief Executive Officer
12 October 2023

Paul Sandland

Chief Financial Officer
12 October 2023

Company number: 3369634

Consolidated Statement of Changes in Shareholders' Equity

For the year ended 30 June 2023

	Issued share capital £m	Share premium account £m	Own Shares £m	Hedging Reserve £m	Foreign currency translation reserve £m	Merger reserve £m	Retained earnings £m	Total equity £m
Year ended 30 June 2022								
At 1 July 2021	1.1	411.6	–	–	(11.9)	84.4	147.7	632.9
Profit for the year	–	–	–	–	–	–	58.2	58.2
Foreign currency translation differences for foreign operations	–	–	–	–	15.7	–	–	15.7
Income tax expense relating to components of other comprehensive income	–	–	–	–	(0.4)	–	–	(0.4)
Total comprehensive income	–	–	–	–	15.3	–	58.2	73.5
Transactions with owners:								
Dividends paid	–	–	–	–	–	–	(44.8)	(44.8)
Share-based payments	–	–	–	–	–	–	2.9	2.9
Shares issued	–	2.3	–	–	–	–	–	2.3
Total contributions by and distributions to owners	–	2.3	–	–	–	–	(41.9)	(39.6)
At 30 June 2022	1.1	413.9	–	–	3.4	84.4	164.0	666.8
Year ended 30 June 2023								
At 1 July 2022	1.1	413.9	–	–	3.4	84.4	164.0	666.8
Loss for the year	–	–	–	–	–	–	(27.9)	(27.9)
Foreign currency cash flow hedge – fair value movements	–	–	–	(2.0)	–	–	–	(2.0)
Foreign currency translation differences for foreign operations	–	–	–	–	(15.0)	–	–	(15.0)
Income tax expense relating to components of other comprehensive income	–	–	–	–	(1.1)	–	–	(1.1)
Total comprehensive expense	–	–	–	(2.0)	(16.1)	–	(27.9)	(46.0)
Reclassified to cost of acquired intangibles	–	–	–	2.0	–	–	–	2.0
Transactions with owners:								
Dividends paid	–	–	–	–	–	–	(51.7)	(51.7)
Share-based payments	–	–	–	–	–	–	2.2	2.2
Shares issued	–	182.1	–	–	–	–	–	182.1
Own share purchases	–	–	(0.2)	–	–	–	–	(0.2)
Total contributions by and distributions to owners	–	182.1	(0.2)	–	–	–	(49.5)	132.4
At 30 June 2023	1.1	596.0	(0.2)	–	(12.7)	84.4	86.6	755.2

Hedging Reserve

The hedging reserve represents the cumulative fair value gains or losses on derivative financial instruments for which cash flow hedge accounting has been applied, net of tax.

Foreign Currency Translation Reserve

The foreign currency translation reserve contains exchange differences on the translation of subsidiaries with a functional currency other than Sterling and exchange gains or losses on the translation of liabilities that hedge the Company's net investment in foreign subsidiaries.

Merger Reserve

The merger reserve represents the excess of fair value over nominal value of shares issued in consideration for the acquisition of subsidiaries where statutory merger relief has been applied in the financial statements of the Parent Company.

Consolidated Statement of Cash Flows

For the year ended 30 June 2023

	Note	2023 £m	2022 £m
Cash flows from operating activities			
Operating profit		6.3	95.5
Non-underlying items	5	158.8	78.8
Underlying operating profit		165.1	174.3
Adjustments for:			
Depreciation	13	13.7	11.1
Amortisation and impairment	2	4.9	5.2
Release of government grant		(0.1)	(0.7)
Loss on disposal of leased assets	7	0.1	0.7
Equity settled share-based payment (income)/expense	26	(0.8)	3.3
Underlying operating cash flow before changes in working capital		182.9	193.9
Increase in inventories		(31.1)	(19.3)
Increase in trade and other receivables		(21.5)	(23.4)
(Decrease)/increase in trade and other payables		(7.6)	14.9
Cash generated from operating activities before interest, taxation & non-underlying items		122.7	166.1
Cash outflows in respect of non-underlying items	5	(13.4)	(2.8)
Cash generated from operating activities before interest and taxation		109.3	163.3
Interest paid		(17.8)	(7.0)
Interest on lease liabilities		(0.5)	(0.5)
Income taxes paid		(27.4)	(32.9)
Net cash generated from operating activities		63.6	122.9
Cash flows from investing activities			
Proceeds from disposal of property, plant and equipment		0.2	–
Interest received		0.8	0.1
Acquisition of subsidiaries (net of cash acquired)		(396.9)	(0.8)
Purchase of property, plant and equipment		(22.8)	(20.3)
Capitalised development expenditure		(2.0)	(1.2)
Purchase of acquired intangible non-current assets		(3.9)	(54.4)
Purchase of other intangible non-current assets		(1.6)	(1.7)
Net cash used in investing activities		(426.2)	(78.3)
Cash flows from financing activities			
Proceeds from the issue of share capital		181.9	2.3
New borrowings		357.4	–
Repayment of borrowings		(166.8)	–
Principal elements of lease payments		(4.3)	(3.6)
Dividends paid	10	(51.7)	(44.8)
Net cash generated from/(used in) financing activities		316.5	(46.1)
Net decrease in cash and cash equivalents		(46.1)	(1.5)
Cash and cash equivalents at start of the year	18	120.9	118.4
Exchange differences on cash and cash equivalents		(0.4)	4.0
Cash and cash equivalents at end of the year	18	74.4	120.9
Reconciliation of net cash flow to movement in net borrowings			
Net decrease in cash and cash equivalents		(46.1)	(1.5)
New borrowings and lease liabilities		(367.2)	(3.8)
Expenses of raising new borrowings		4.1	–
Repayment of borrowings and lease liabilities		171.6	4.1
Exchange differences on cash and cash equivalents		(0.4)	4.0
Retranslation of foreign borrowings		18.2	(11.2)
Other non-cash changes		(2.1)	0.4
Movement in net borrowings in the year		(221.9)	(8.0)
Net borrowings at start of the year		(208.2)	(200.2)
Net borrowings at end of the year	27	(430.1)	(208.2)

Underlying cash conversion is defined as cash generated from operating activities before interest and taxation as a percentage of underlying operating profit.

Notes to the Consolidated Financial Statements

1. Accounting Policies

Dechra Pharmaceuticals PLC is a public limited company, which is limited by shares and is listed on the London Stock Exchange and incorporated and domiciled in the United Kingdom. The address of its registered office is 24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, CW9 7UA England. The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These have been applied consistently in all years presented with the exception of the adoption of new accounting standards as outlined below.

(a) Statement of Compliance

The consolidated financial statements have been prepared and approved by the Directors in accordance with UK-adopted International Accounting Standards and the requirements of the Companies Act 2006 as it applies to companies reporting under those standards. The Company has elected to prepare its Parent Company financial statements in accordance with FRS 101 and they are separately presented on pages 235 to 246.

(b) Basis of Preparation

The consolidated financial statements are presented in Sterling, rounded to the nearest 0.1 million. They are prepared on a going concern basis and under the historical cost convention, except where IFRSs require an alternative treatment. The principal variations relate to derivative financial instruments, cash settled share-based transactions and contingent consideration. The preparation of consolidated financial statements in accordance with IFRSs requires the use of accounting estimates and for management to exercise its judgement in the process of applying the Group's accounting policies. These judgements and estimates are based on historical experience and management's best knowledge of the amounts, events or actions under review and the actual results may ultimately differ from these estimates. Areas involving a high degree of judgement or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements, are, where necessary, disclosed separately.

Going Concern

The Directors have a reasonable expectation that the Group and Company has adequate resources to continue in operational existence for the foreseeable future and will continue to be able to meet its liabilities as they fall due, within 12 months of the date of approval of these financial statements. Accordingly, they continue to adopt the going concern basis of accounting in preparing these annual financial statements.

In reaching this conclusion, the Directors have given due regard to the following:

- The Group's business activities, together with factors likely to impact future growth and operating performance including the principal risks and uncertainties, and an assessment of a number of severe but plausible stress tests on these areas (as set out on pages 79 to 82);
- The current and projected future financial position of the Group, its cash flows, available cash resources and committed debt facilities and compliance with the financial covenants associated with the Group's borrowings, which are described in the financial statements;
- Subsequent events (see note 34 and below).

On 2 June 2023, the boards of directors of Dechra and Freya Bidco Limited ("Bidco") announced that they had reached agreement on the terms and conditions of a recommended cash acquisition by Bidco of the entire issued, and to be issued, ordinary share capital of Dechra (the "Acquisition"). The Acquisition is being implemented by means of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the Scheme) and is subject to the terms and conditions set out in the circular in relation to the Scheme sent to Dechra Shareholders dated 26 June 2023 (the Scheme Document). As announced by Dechra on 20 July 2023, the Scheme and its implementation were approved by the requisite majority of Scheme Shareholders and Dechra Shareholders (as applicable) on 20 July 2023 and the Acquisition is expected to complete later in the calendar year, after the date of approval of the Annual Report and Accounts. The going concern assessment of the Group and Company is therefore subject to uncertainties relating to the potential change in ownership of the Group and Company and the actual funding requirements and financing arrangements post completion. For this reason, the Directors cannot reasonably predict the financial position of the Group and Company post-completion, including the details of any financing arrangements related to the transaction that could affect the Group and Company. This indicates the existence of a material uncertainty which may cast significant doubt on the Group and Company's ability to continue as a going concern. As noted above, the financial statements do not however include the adjustments that would result if the Group and Company were unable to continue as a going concern.

Notwithstanding this uncertainty, based on the circumstances described above, the Directors have a reasonable expectation that the Group and Company has adequate resources to continue in operational existence for the foreseeable future and the accounts are prepared on the assumption that the Group and Company is a going concern.

Notes to the Consolidated Financial Statements

1. Accounting Policies continued

(b) Basis of Preparation (continued)

Critical Judgements in Applying the Group's Accounting Policies and Key Sources of Estimation Uncertainty

In the process of applying the Group's accounting policies, the Directors have made the following estimates where the actual outcome may differ from that calculated. The Group has made no critical judgements in applying the Group's accounting policies. The key sources of estimation uncertainty at the balance sheet date, that have a significant risk of causing material adjustment to the carrying values of the assets and liabilities within the next financial year, are summarised below.

Area	Key sources of estimation uncertainty	Note reference	Accounting policy reference
Valuation of licensing agreements and associated contingent consideration	Timing, likelihood and quantum of future royalty cash flows, timing of future approval milestones and the determination of an appropriate discount rate	30	1(p)
Valuation of acquired intangibles as part of a business combination	Timing, likelihood and quantum of future cash flows, and the determination of an appropriate discount rate	29	1(g)
Valuation of In-Process Research and Development intangibles	Timing, likelihood and quantum of future cash flows, and the determination of an appropriate discount rate	14	1(j)

Non-underlying Items

The Group presents a number of non-GAAP measures. This is to allow investors to understand the underlying performance of the Group, excluding items associated with areas such as: amortisation of acquired intangibles; downward remeasurement where there is not an intangible asset and accounting for the passage of time in respect of contingent considerations; impairment of assets; cloud computing arrangement costs; expenses relating to acquisition and subsequent integration activities; loss on extinguishment of debt; and the revaluation of deferred tax balances following substantial tax legislation changes. Management utilises non-underlying items to isolate the impact of exceptional, one-off or non-trading related items and consequently the classification of these items requires judgement. Further details can be found in note 5.

New Standards and Amendments to Standards or Interpretations

A number of amendments to IFRSs became effective for the financial year beginning on 1 July 2022. The Group has applied the amendments to IAS1, Practice Statement 2, IAS8 and IAS12 (deferred tax related to assets and liabilities arising from a single transaction and International tax reform pillar 2 model rules). None of these amendments had any impact on the Group's accounting policies or required retrospective adjustments.

(c) Basis of Consolidation

Subsidiary Undertakings

Subsidiary undertakings are fully consolidated from the date on which control is transferred to the Group. They cease to be consolidated from the date that the Group no longer has control. All subsidiary undertakings have been consolidated. Inter-company transactions, balances and unrealised gains and losses on transactions between Group companies are eliminated on consolidation. The financial statements of all subsidiary undertakings are prepared to the same reporting date as the Company, with the exception of Genera Pharma d.o.o. and Dechra Productos Veterinarios, S.A. de C.V. (all of which prepare local financial statements to 31 December each year, in line with local tax authority regulations).

Associates

Associates are all entities over which the Group has significant influence but not control, generally accompanying a shareholding of between 20% and 50% of the voting rights. Investments in associates are accounted for using the equity method of accounting. Under the equity method, the investment is initially recognised at cost, and the carrying amount is increased or decreased to recognise the investor's share of the change in net assets of the investee after the date of acquisition. Intangible assets identified as part of the notional purchase price allocation are amortised over the useful life of each asset, with the Group's share recognised as a charge in the income statement.

The Group's share of post-acquisition profit or loss is recognised in the income statement, and its share of post-acquisition movements in other comprehensive income is recognised in other comprehensive income with a corresponding adjustment to the carrying amount of the investment. Distributions received from an associate reduce the carrying amount of the investment.

1. Accounting Policies continued

(c) Basis of Consolidation (continued) Associates (continued)

The Group determines at each reporting date whether there is any objective evidence that the investment in the associate is impaired. If this is the case, the Group calculates the amount of impairment as the difference between the recoverable amount of the associate and its carrying value and recognises the amount adjacent to share of profit/(loss) of associates in the income statement.

Gains and losses resulting from upstream and downstream transactions between the Group and its associate are only recognised to the extent realised. Any unrealised gains or losses are eliminated, to the extent of the Group's interest in the associate. Accounting policies of associates have been aligned where necessary to ensure consistency with the policies adopted by the Group.

(d) Foreign Currency Translation

(i) Functional and Presentational Currency

The consolidated financial statements are presented in Sterling, which is the Group's presentational currency, and are rounded to the nearest hundred thousand, except where it is deemed relevant to disclose the amounts to the nearest million. Items included in the financial statements of each of the Group's entities are measured using the currency of the primary economic environment in which the entity operates (the functional currency).

(ii) Foreign Currency Translation

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the date of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies are recognised in the income statement, with the exception of differences on transactions that are subject to effective cash flow hedges, which are recognised in other comprehensive income.

(iii) Foreign Operations

The income and expenses of foreign operations are translated to Sterling at the average rate for the year being reported. The assets and liabilities of foreign operations are translated to Sterling at the closing rate at the reporting date. Foreign currency differences on all translations are recognised in other comprehensive income in the foreign currency translation reserve, a separate component of equity.

Goodwill and fair value adjustments arising on the acquisition of a foreign entity are treated as assets and liabilities of the foreign entity and translated at the closing rate. On disposal of a foreign entity, accumulated exchange differences previously recognised in other comprehensive income are recognised in the income statement in the same year in which the gain or loss on disposal is recognised.

(e) Accounting for Financial Assets and Liabilities, Derivative Financial Instruments and Hedging Activities Financial Assets

At initial recognition, the Group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (FVPL), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVPL are expensed in profit or loss.

Management determines the classification of financial assets at initial recognition in accordance with IFRS 9, which defines three categories that debt instruments may be classified as, depending on the purpose for which the assets are held. These categories are:

- Amortised cost;
- Fair value through other comprehensive income (FVOCI); and
- Fair value through the profit and loss (FVPL).

Amortised cost relates to assets that are held for collection of contractual cash flows. Where those cash flows represent solely payments of principal and interest, they are measured at amortised cost. Interest income from these financial assets is included in finance income using the effective interest rate method. Any gain or loss arising on derecognition is recognised directly in the income statement. All material financial assets of the Group are held at amortised cost.

Financial assets are derecognised when the rights to receive cash flows from the assets have expired or have been transferred and the Group has transferred substantially all risks and rewards of ownership. Gains and losses (both realised and unrealised) arising from changes in the value of financial assets held at fair value through the income statement are included in the income statement in the year in which they arise.

Notes to the Consolidated Financial Statements

1. Accounting Policies continued

(e) Accounting for Financial Assets and Liabilities, Derivative Financial Instruments and Hedging Activities (continued)

Derivative Financial Instruments

The Group uses derivative financial instruments to manage its exposure to foreign exchange rate risks and interest rate risks. In accordance with its treasury policy, the Group does not hold or issue derivative financial instruments for speculative purposes. However, derivatives that do not qualify for hedge accounting are accounted for as trading instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are remeasured to fair value at each reporting date.

Cash Flow Hedges

Changes in the fair value of derivative financial instruments designated as cash flow hedges are recognised in other comprehensive income to the extent that the hedge is effective. To the extent that the hedge is ineffective, changes in fair value are recognised immediately in the income statement. If the hedging instrument no longer meets the criteria for hedge accounting, expires or is sold, terminated or exercised, then hedge accounting is discontinued prospectively. The cumulative gain or loss previously recognised in other comprehensive income remains there until the forecast transaction occurs.

Net Investment Hedge

For hedges of net investments in foreign operations where the hedge is effective, movements are recognised in other comprehensive income. Ineffectiveness is recognised in the income statement. Gains and losses accumulated in equity are included in the income statement when the foreign operation is partially disposed of or sold.

Trade Receivables

Trade receivables are recorded at aggregate invoice value (including value added tax or other sales taxes) less loss allowances, which are calculated using the expected loss model. Where trade receivables contain a significant financing component, they are then carried at amortised cost using the effective interest rate method, less loss allowances. Other receivables are recorded at their transaction value.

The Group assesses, on a forward-looking basis, the expected credit losses associated with its trade and other receivables. The Group applies the simplified approach permitted by IFRS 9, which requires expected lifetime losses to be recognised from initial recognition of the receivables. Where there is a specific risk surrounding a receivable, then a credit loss allowance of 100% is applied.

Trade and Other Payables

Trade and other payables are initially recognised at fair value and subsequently at amortised cost.

Borrowings and Borrowing Costs

Borrowings are recognised initially at fair value net of directly attributable transaction costs incurred. Borrowings are subsequently stated at amortised cost. Any difference between the proceeds (net of transaction costs) and the redemption value is recognised in the income statement over the period of the borrowings using the effective interest method. Borrowings are classified as current liabilities unless the Group has a right to defer settlement of the liability for at least 12 months after the reporting date.

Borrowing costs directly attributable to the acquisition, construction, or production of qualifying assets, which are assets that take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use. All other borrowing costs are recognised in the income statement in the year in which they are incurred.

(f) Property, Plant and Equipment

Owned Assets

Items of property, plant and equipment are stated at cost less accumulated depreciation and impairment losses.

Depreciation

Depreciation is charged to the income statement on a straight-line basis over the estimated useful life of each part of an item of property, plant and equipment. Land is not depreciated. Assets in the course of construction are not depreciated until the date the assets become available for use. The estimated useful lives are as follows:

- freehold buildings 25 years
- short leasehold buildings period of lease
- motor vehicles 4 years
- plant and fixtures 3 to 15 years

The residual value, where significant, is reassessed annually.

1. Accounting Policies continued

(g) Intangible Assets

Goodwill

All business combinations are accounted for by applying the purchase method. Goodwill represents amounts arising on acquisition of subsidiaries and associates. In respect of business acquisitions that occurred before 1 July 2004, goodwill represents the difference between the cost of the acquisition and the fair value of the separable assets, liabilities and contingent liabilities acquired.

Acquisitions after this date fall under the provisions of 'IFRS 3 Business Combinations'. For these acquisitions, transaction costs, other than share and debt issue costs, are expensed as incurred and subsequent adjustments to the fair value of consideration payable are recognised in the income statement.

Goodwill is stated at cost less any accumulated impairment losses. Goodwill is not amortised but is allocated to cash generating units and is tested annually for impairment.

Research and Development Costs

Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognised in the income statement as an expense as incurred.

The Group is also engaged in development activity with a view to bringing new pharmaceutical products to market. Due to the strict regulatory process involved, there is inherent uncertainty as to the technical feasibility of development projects often until regulatory approval is achieved, with the possibility of failure even at a late stage. The Group considers that this uncertainty means that the criteria for capitalisation are not met unless it is highly probable that regulatory approval will be achieved and the project is commercially viable. Internally generated costs of development are capitalised, once the criteria are met, in the consolidated statement of financial position unless those costs cannot be measured reliably or it is not probable that future economic benefits will flow to the Group, in which case the relevant costs are expensed to the income statement as incurred.

Where development costs are capitalised, the expenditure includes the cost of materials, direct labour and an appropriate proportion of overheads. Capitalised development expenditure is stated at cost less accumulated amortisation and impairment losses.

Acquired Intangible Assets

Intangible assets recognised as a result of a business combination are stated at fair value at the date of acquisition less accumulated amortisation and impairment losses.

Intangible assets that are acquired by the Group as a result of an asset acquisition are stated at cost (including future milestone and royalty payments as applicable) less accumulated amortisation and impairment losses. Contingent considerations are remeasured at each reporting date and any downward remeasurement of the related liability is adjusted against the intangible asset, with any excess over the carrying value of the intangible asset recognised in the income statement. Any upwards remeasurement is recognised as an increase to the intangible asset. Refer to note 1 (p).

Other Intangible Assets

Other intangible assets (which primarily include software and marketing rights) are stated at cost less accumulated amortisation and impairment losses. Expenditure on internally generated goodwill and other intangible assets is recognised in the income statement as an expense as incurred.

Intangible Assets Subsequent Expenditure

Subsequent expenditure on capitalised intangible assets is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates or extends the asset life. All other expenditure is expensed as incurred.

Amortisation

Amortisation is charged to the income statement on a straight-line basis over the estimated useful lives of intangible assets unless such lives are indefinite or as otherwise stated below. Goodwill and intangible assets with an indefinite useful life are not amortised but are systematically tested for impairment at each consolidated statement of financial position date. Other intangible assets are amortised from the date that they are available for use. Assets in the course of construction are not amortised until the date the assets become available for use.

Notes to the Consolidated Financial Statements

1. Accounting Policies continued

(g) Intangible Assets (continued)

The estimated useful lives are as follows:

• software	5 to 7 years
• capitalised development costs	5 to 10 years or period of patent
• patent rights	period of patent
• marketing authorisations	indefinite life or period of marketing authorisation
• product rights	10 to 18 years
• commercial relationships	7 years
• brand	3 to 10 years
• acquired capitalised development costs	5 to 15 years
• pharmacological process	10 years

The pharmacological process from the acquisition of Putney Inc. and capitalised developed technology from the acquisition of AST Farma B.V. and Le Vet Beheer B.V. are amortised on a reducing balance method at a rate of 20% based on the expected profile of future cash flows. All amortisation on a reducing balance methodology is recognised within selling and general administrative expenses with the exception of that in respect of the pharmacological process which is recognised within research and development expenses.

Where an other intangible asset has been remeasured, the adjustment is amortised prospectively over the remaining useful life of the asset.

The amortisation of the intangible assets is classified as an administrative expense because they relate to the right to sell and distribute the product. Within acquired intangible assets the product rights encompass market authorisations, and the capitalised development costs encompass product authorisations subject to regulatory approval. The pharmacological process is classified as a research and development expense as it relates to the process of taking a product through to registration.

When considering the basis of amortisation for acquired intangible assets, management considers a number of factors: the different market conditions which surround the intangible assets; the age of the products within developed technology; and their corresponding place within the lifecycle of the product.

(h) Inventories

Inventories are stated at the lower of cost and net realisable value. Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.

The cost of inventories is determined on the first-in, first-out principle and includes expenditure incurred in acquiring the inventories and bringing them to their existing location and condition. In the case of manufactured inventories and work in progress, cost includes an appropriate share of labour and overheads based on normal operating capacity.

(i) Cash and Cash Equivalents

Cash and cash equivalents comprise cash balances and call deposits. Bank overdrafts that are repayable on demand and form an integral part of the Group's cash management are included as a component of cash and cash equivalents for the purpose of the statement of cash flows.

(j) Impairment of Non-current Assets

The carrying amounts of the Group's non-current assets are reviewed at each consolidated statement of financial position date to determine whether there is any indication of impairment. If any such indication exists, the asset's recoverable amount is estimated.

The recoverable amount of assets is the greater of their fair value less cost to sell, and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using an appropriate rate that reflects current market assessments of the time value of money and the risks specific to the asset. For an asset that does not generate largely independent cash inflows, the recoverable amount is determined for the cash generating unit to which the asset belongs.

For goodwill, assets that have an indefinite useful life and intangible assets that are not yet available for use, the recoverable amount is estimated at each consolidated statement of financial position date and when there is an indication that the asset is impaired.

1. Accounting Policies continued

(j) Impairment of Non-current Assets (continued)

An impairment loss is recognised whenever the carrying amount of an asset or its cash generating unit exceeds its recoverable amount. Impairment losses are recognised in the income statement.

Impairment losses recognised in respect of cash generating units are allocated first to reduce the carrying amount of any goodwill allocated to the cash generating units (group of units), and then to reduce the carrying amount of the other assets in the units (group of units) on a pro rata basis.

An impairment loss in respect of goodwill is not reversed.

In respect of other assets, an impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount.

An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised.

(k) Dividends Paid

Dividends are recognised in the year in which they are approved by the Company's shareholders or, in the case of an interim dividend, when the dividend is paid.

(i) Employee Benefits

Pensions

The Group operates a stakeholder personal pension scheme for certain employees. Obligations for contributions are recognised as an expense in the income statement as incurred.

Dechra Veterinary Products SAS and Dechra Veterinary Products B.V. participate in state-run pension arrangements. These are not considered to be material to the Group financial statements and are accounted for as defined contribution schemes, with contributions being recognised as an expense in the income statement as incurred.

Share-based Payment Transactions

The Group operates a number of equity settled share-based payment programmes that allow employees to acquire shares in the Company. The Group also operates a Long Term Incentive Plan for Directors and Senior Executives.

The fair value of shares or options granted is recognised as an employee expense over the vesting period on a straight-line basis in the income statement with a corresponding movement to equity reserves. Fair values are determined by use of an appropriate pricing model and by reference to the fair value of the options granted. The amount to be expensed over the vesting period is adjusted to reflect the number of awards for which the related service and non-market vesting conditions are expected to be met, such that the amount ultimately recognised as an expense is based on the number of awards that meet the related service and non-market performance conditions at the vesting date.

At each consolidated statement of financial position date, the Group revises its estimates of the number of share incentives that are expected to vest. The impact of the revisions of original estimates, if any, is recognised in the income statement, with a corresponding adjustment to equity reserves, over the remaining vesting period.

The fair values of grants under the Long Term Incentive Plan have been determined using the Monte Carlo simulation model, as performed by a qualified third party valuation expert.

The fair values of options granted under all other share option schemes have been determined using the Black-Scholes option pricing model, as performed by a qualified third party valuation expert.

When the options are exercised, the Company issues new shares. The proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and share premium.

National Insurance contributions payable by the Company on the intrinsic value of share-based payments at the date of exercise are treated as cash settled awards and revalued to market price at each consolidated statement of financial position date.

Bonus and Commission Payments

The Group operates sales incentives schemes for certain employees and third party sales representatives in particular territories. The related bonuses and commissions are accrued in line with the related sales revenues.

Notes to the Consolidated Financial Statements

1. Accounting Policies continued

(m) Revenue Recognition

Revenue from the sale of goods is measured at the transaction price that the entity is entitled to. The primary performance obligation is the transfer of goods to the customer. Revenue from the sale of goods is recognised when control of the goods is transferred to the customer, at an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods.

As sales arrangements differ from time to time (for example by customer and by territory), each arrangement is reviewed to ensure that revenue is recognised when control of the goods has passed to the customer.

This review and the corresponding recognition of revenue encompass a number of factors which include, but are not limited to the following:

- reviewing delivery arrangements and whether the buyer has accepted title, recognising revenue at the point at which full title has passed; and/or
- where distribution arrangements are in place, recognising revenue when the goods pass to the third party customer (for example by reviewing insurance arrangements) at the point at which title has passed.

Provision for rebates, returns, discounts and other variable consideration is reflected in the transaction price at the point of recognition to the extent that it is highly probable there will not be a significant reversal. The methodology and assumptions used to estimate rebates and returns are based on the most likely method of calculation. This is adjusted in light of contractual and legal obligations, historical trends, past experience and projected market conditions. Market conditions are evaluated using wholesaler and other third party analysis, and internally generated information.

(n) Leases

The Group leases various offices, warehouses, equipment and vehicles. Rental contracts are typically made for fixed periods of three to five years, but may have extension options as described below.

Contracts may contain both lease and non-lease components. The Group allocates the consideration in the contract to the lease and non-lease components based on their relative stand-alone prices.

Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions. The lease agreements do not impose any covenants other than the security interests in the leased assets that are held by the lessor. Leased assets may not be used as security for borrowing purposes.

Extension and Termination Options

Extension and termination options are included in a number of property and equipment leases across the Group. These are used to maximise operational flexibility in terms of managing the assets used in the Group's operations. The majority of extension and termination options held are exercisable by both the Group and the respective lessor.

Measurement

Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments:

- fixed payments (including in-substance fixed payments), less any lease incentives receivable;
- variable lease payments that are based on an index or a rate, initially measured using the index or rate as at the commencement date;
- amounts expected to be payable by the Group under residual value guarantees;
- the exercise price of a purchase option if the Group is reasonably certain to exercise that option; and
- payments of penalties for terminating the lease, if the lease term reflects the Group exercising that option.

Lease payments to be made under reasonably certain extension options are also included in the measurement of the liability.

The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be determined, the lessee's incremental borrowing rate is used, being the rate that the individual lessee would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions. The lease liability is not materially sensitive to a reasonable change in discount rate and therefore will not represent a critical accounting estimate presented within the Annual Report.

Lease payments are allocated between principal and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each year.

1. Accounting Policies continued

(n) Leases (continued)

Right-of-use assets are measured at cost comprising the following:

- the amount of the initial measurement of lease liability;
- any lease payments made at or before the commencement date less any lease incentives received;
- any initial direct costs; and
- restoration costs.

Right-of-use assets are generally depreciated over the shorter of the asset's useful life and the lease term on a straight-line basis.

Payments associated with short term leases of equipment and vehicles and all leases of low-value assets are recognised on a straight-line basis as an expense in profit or loss. Short term leases are leases with a lease term of 12 months or less. Low-value assets comprise IT equipment and small items of office furniture.

(o) Net Financing Costs

Net financing costs comprise interest payable on borrowings, unwinding of discount on provisions and cost of debt on contingent considerations measured, interest receivable on funds invested, gains and losses on hedging instruments that are recognised in the income statement (see accounting policy (e)) and gains or losses on the retranslation of financial assets and liabilities denominated in foreign currencies. Interest income is recognised in the income statement as it accrues. The Group capitalises borrowing costs directly attributable to the acquisition, construction or production of a qualifying asset as part of the cost of that asset.

(p) Contingent Considerations

The Group's accounting for contingent consideration in respect of the acquisition of intangible assets in the form of licensing agreements where the product has not been registered and launched in all key markets is consistent with the principles of IFRS 3 and IFRIC 1. The contingent consideration is initially and subsequently measured at fair value. Subsequent fair value movements in remeasuring the contingent consideration related to changes in the cost of debt and foreign exchange are recognised as finance expenses in the income statement. All other movements are considered related to the utility of the asset and therefore are adjusted against the cost of the asset.

For licensing agreements where the product has been registered and launched in all key markets, an intangible asset is initially recognised, at the date of acquisition, at the cost paid. Variable payments (normally in the form of sales based royalties to another third party) are recognised as an expense in cost of sales as the sales are made.

(q) Provisions

Provisions for legal claims, dilapidations, environmental remediation, deferred rent and advanced grants for property, plant and equipment are recognised when: the Group has a present legal or constructive obligation as a result of past events; it is probable that an outflow of resources will be required to settle the obligation; and the amount can be reliably estimated. Provisions are not recognised for future operating losses. Where there are a number of similar obligations, the likelihood that an outflow will be required on settlement is determined by considering the class of obligations as a whole. A provision is recognised even if the likelihood of an outflow with respect to any one item included in the same class of obligations may be small.

Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the obligation. The increase in the provision due to passage of time is recognised as an interest expense.

(r) Basis of Charge for Taxation

Income tax expense comprises current and deferred tax. Current and deferred taxes are recognised in the income statement except to the extent they relate to a business combination or items recognised directly in equity or in other comprehensive income.

Current tax is the expected tax payable on the taxable income for the year using tax rates enacted or substantively enacted at the consolidated statement of financial position date, and any adjustment to tax payable in respect of previous years.

Notes to the Consolidated Financial Statements

1. Accounting Policies continued

(r) Basis of Charge for Taxation (continued)

Deferred tax is provided using the consolidated statement of financial position liability method and represents the tax payable or recoverable on most temporary differences which arise between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes (the tax base). Temporary differences are not provided on: goodwill that is not deductible for tax purposes; the initial recognition of assets or liabilities that affect neither accounting nor taxable profit and do not arise from a business combination; and differences relating to investments in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realisation or settlement of the carrying amount of assets and liabilities, and is based upon tax rates enacted or substantively enacted at the consolidated statement of financial position date.

A deferred tax asset is recognised only to the extent that it is probable that future taxable profits will be available against which the asset can be utilised. Deferred tax assets are reduced to the extent that it is not probable that the related tax benefit will be realised against future taxable profits. The carrying amounts of deferred tax assets are reviewed at each consolidated statement of financial position date.

In respect of uncertain tax positions, where an outflow of funds is believed to be probable and a reliable estimate of the outcome of the dispute can be made, management provides for its best estimate of the liability. Such provisions are measured using either the most likely outcome method, or the expected value method depending on management's judgement of which method better predicts the resolution of the uncertainty. The methodology will be reviewed in each case upon the receipt of any new information.

The estimated annual benefit of global intellectual property and innovation incentives is accounted for within current and deferred tax.

Current and deferred tax credits received in respect of share-based payments are recognised in the income statement to the extent that they do not exceed the standard rate of taxation on the income statement charge for share-based payments. Credits in excess of the standard rate of taxation are recognised directly in equity.

(s) Earnings per Share

The Group presents basic and diluted earnings per share (EPS) data for its ordinary shares. Basic EPS is calculated by dividing the profit attributable to ordinary shareholders of the Company by the weighted average number of ordinary shares in issue during the year. Diluted EPS is determined by adjusting the profit attributable to ordinary shareholders and the weighted average number of ordinary shares in issue for the effects of all potential dilutive ordinary shares, which comprise share options granted to employees.

The Group has also chosen to present an alternative EPS measure, with profit adjusted for non-underlying items. A reconciliation of this alternative measure to the statutory measure required by IFRS is given in the Financial Review on page 45. A breakdown of the non-underlying items is given in notes 3, 4 and 5.

2. Operating Segments

As discussed below, the Group has four reportable segments which are based on information provided to the Board of Directors, deemed to be the Group's chief operating decision maker. In previous periods the International Pharmaceuticals operating segment had been aggregated into the European Pharmaceuticals segment on the basis of similar products, production processes, customers and overall regulatory environments. Given the significance of this operating segment to the Group, International Pharmaceuticals is disclosed as a separate reporting segment, and the prior year figures have been restated to align with this disclosure.

The European Pharmaceuticals Segment comprises Dechra Veterinary Products EU and includes our manufacturing units based in Bladel (The Netherlands), Skipton (UK) and Zagreb (Croatia). This Segment operates in Europe and manufactures and markets Companion Animal Products (CAP), Equine, Food producing Animal Products (FAP) and Nutrition. This Segment also includes third party manufacturing and other revenues from non-core activities.

The North American Pharmaceuticals Segment consists of Dechra Veterinary Products (DVP) US, DVP Canada, and DVP Mexico, which sells CAP, Equine and FAP in those territories. The Segment also includes our manufacturing units based in Pomona (California), Melbourne (Florida) and Fort Worth (Texas), and includes third party manufacturing and other revenues from non-core activities.

The International Pharmaceuticals Segment consists of Dechra Veterinary Products (DVP) ANZ, DVP Brazil, DVP Korea, and DVP Export. This Segment operates internationally and manufactures and markets CAP, Equine, FAP and Nutrition.

2. Operating Segments continued

The Pharmaceuticals Research and Development Segment includes all of the Group's pharmaceutical research and development activities. This Segment has no revenue. Reconciliation of reportable segment revenues, profit or loss and liabilities and other material items:

	2023 £m	2022 £m
Revenue by segment		
European Pharmaceuticals	343.5	323.2
NA Pharmaceuticals	330.9	275.1
International Pharmaceuticals	87.1	83.5
	761.5	681.8
Underlying operating profit/(loss) by segment		
European Pharmaceuticals	107.7	103.4
NA Pharmaceuticals	96.2	87.7
International Pharmaceuticals	25.5	28.1
Pharmaceuticals Research and Development	(57.5)	(32.4)
Underlying segment operating profit	171.9	186.8
Corporate and other unallocated costs	(6.8)	(12.5)
Underlying operating profit	165.1	174.3
Amortisation of acquired intangibles	(71.1)	(72.8)
Cloud computing arrangement costs	(8.5)	(2.8)
Impairment of assets	(69.6)	(2.9)
Unwind of fair value uplift of acquisition inventory	(3.3)	–
Remeasurement of contingent consideration	1.2	–
Expenses relating to acquisitions and subsequent integration activities	(7.5)	(0.3)
Total operating profit	6.3	95.5
Finance income	4.5	5.7
Finance expense	(46.0)	(22.3)
Share of loss of investments accounted for using the equity method	(0.9)	(1.3)
(Loss)/profit before taxation	(36.1)	77.6
Total liabilities by segment		
European Pharmaceuticals	(122.3)	(132.9)
NA Pharmaceuticals	(82.0)	(110.6)
International Pharmaceuticals	(12.0)	(8.4)
Pharmaceuticals Research and Development	(7.4)	(4.7)
Segment liabilities	(223.7)	(256.6)
Corporate loans and revolving credit facility	(487.6)	(313.7)
Corporate accruals and other payables	(15.1)	(8.2)
Current and deferred tax liabilities	(87.8)	(48.0)
	(814.2)	(626.5)

Notes to the Consolidated Financial Statements

2. Operating Segments continued

	2023 £m	2022 £m
Revenue by product category		
CAP	562.6	508.4
Equine	65.2	49.5
FAP	89.0	78.8
Nutrition	38.5	35.0
Other	6.2	10.1
	761.5	681.8
Additions to intangible non-current assets by segment (including through business combinations)		
European Pharmaceuticals	2.3	16.1
NA Pharmaceuticals	411.0	75.1
International Pharmaceuticals	0.9	7.4
Pharmaceuticals Research and Development	0.2	0.3
Corporate and central costs	0.4	–
	414.8	98.9
Additions to Property, Plant and Equipment by segment (including through business combinations)		
European Pharmaceuticals	17.4	18.0
NA Pharmaceuticals	52.6	2.4
International Pharmaceuticals	3.9	2.5
Pharmaceuticals Research and Development	2.3	0.5
Corporate and central costs	0.7	0.8
	76.9	24.2
Depreciation, impairment and amortisation by segment		
European Pharmaceuticals	42.2	54.6
NA Pharmaceuticals	106.0	26.1
International Pharmaceuticals	9.3	8.8
Pharmaceuticals Research and Development	0.6	0.5
Corporate and central costs	0.7	0.8
	158.8	90.8
The total depreciation, impairment and amortisation charge is made up of the following:		
Non-underlying		
Amortisation and impairment – selling, general and administrative expenses	136.9	70.8
Amortisation – research and development expenditure	3.3	3.7
	140.2	74.5
Underlying		
Amortisation and impairment	4.9	5.2
Depreciation	13.7	11.1
	18.6	16.3

2. Operating Segments continued

Geographical Information

The following table shows revenue based on the geographical location of customers and non-current assets based on the country of domicile of the entity holding the asset:

	2023 Revenue £m	2023 Non- current assets £m	2022 Revenue £m	2022 Non- current assets £m
UK	60.7	38.4	58.2	31.8
Germany	68.7	2.7	62.3	2.9
Rest of Europe	224.3	348.0	212.9	378.8
USA	310.1	583.5	258.3	278.3
Rest of World	97.7	128.9	90.1	157.1
	761.5	1,101.5	681.8	848.9

3. Finance Income

	2023 £m	2022 £m
Underlying		
Finance income arising from:		
– Cash and cash equivalents	0.8	0.1
– Foreign exchange gains	–	5.6
Underlying finance income	0.8	5.7
Non-underlying		
Finance income arising from:		
– Foreign exchange gains on contingent consideration	3.7	–
Non-underlying finance income	3.7	–
Total finance income	4.5	5.7

4. Finance Expense

	2023 £m	2022 £m
Underlying		
Finance expense arising from:		
– Financial liabilities at amortised cost	22.6	8.3
– Lease liability interest	0.5	0.5
– Foreign exchange losses	1.5	–
Underlying finance expense	24.6	8.8
Non-underlying		
Finance expense arising from:		
– Foreign exchange losses on contingent consideration	–	10.1
– Unwind of discount associated with contingent consideration	20.8	3.4
– Loss on extinguishment of debt	0.6	–
Non-underlying finance expense	21.4	13.5
Total finance expense	46.0	22.3

Notes to the Consolidated Financial Statements

5. Non-underlying Items

Non-underlying items charged/(credited) comprise:

	2023 £m	2022 £m
Amortisation of acquired intangibles		
– classified within selling, general and administrative expenses	67.8	69.1
– classified within research and development expenses	3.3	3.7
Cloud computing arrangement costs	8.5	2.8
Impairment of assets	69.6	2.9
Expenses relating to acquisitions and subsequent integration activities	7.5	0.3
Unwind of fair value uplift of inventory on acquisitions	3.3	–
Remeasurement of contingent consideration	(1.2)	–
Non-underlying operating loss	158.8	78.8
Amortisation of notional acquired intangibles from equity accounting for associates	0.8	0.7
Share of realised non-underlying profit of investments accounted for using the equity method	(0.9)	(0.6)
Loss on extinguishment of debt	0.6	–
Foreign exchange (gains)/losses on contingent consideration	(3.7)	10.1
Unwind of discount associated with contingent consideration	20.8	3.4
Non-underlying loss before tax	176.4	92.4
Tax on non-underlying loss before tax item	(40.6)	(21.1)
Revaluation of deferred tax balances following the change in the US, Dutch and UK tax rates	–	2.2
Non-underlying loss after tax	135.8	73.5

Amortisation of acquired intangibles reflects the amortisation of the fair values of future cash flows recognised on acquisition in relation to the identifiable intangible assets acquired.

Cloud computing arrangement costs of £8.5 million relate to the costs of the programme to implement the Manufacturing and Supply function's new ERP and Electronic Quality Management systems, the total future cost of which is expected to be £23.9 million over the next four years. Included within underlying administrative expenses is £0.7 million of other cloud computing arrangement costs which predominantly relate to the integration of the Group HR systems with the Group's global payroll platform. The £8.5 million of non-underlying expenses have been settled in the year.

Impairment of assets of £69.6 million relate to an acquired intangible asset (£69.1 million) for one of the near term products in the Piedmont product pipeline, and the associated inventory write off of £0.5 million. The prior year charge predominantly related to the impairment of certain assets prior to the sale of the Agricultural Chemicals business in January 2022 (£1.0 million) and the impairment of a small number of In-Process Research and Development assets recognised on the acquisition of AST Farma B.V. and Le Vet Beheer B.V. (£1.7 million).

Expenses relating to acquisitions and subsequent integration activities represent costs incurred during the acquisition of Piedmont Animal Health, Inc. (£0.2 million) and the Med-Pharmex Holdings, Inc. group of companies (£2.8 million). No further significant expenditure is expected in relation to these acquisitions. On the acquisition of Ampharmco, LLC, the Group established a fair value provision of £0.5 million for dilapidations of a warehouse property. This has been fully released in the year. Acquisition expenses also include costs associated with the pending acquisition of the Company by Freya Bidco Limited (£5.0 million), which includes £3.5 million relating to accelerated charges on equity and cash settled share based transactions. Further expenses of £26.0 million are expected in the 2024 financial year, of which £25.0 million are contingent on the completion of the acquisition. Acquisition and integration expenses of £4.4 million have been settled in the year.

The fair value uplift of inventory acquired through business combinations is recognised in accordance with IFRS 3 'Business Combinations' to record the inventory acquired at fair value and its subsequent release into the income statement.

The remeasurement of the contingent consideration balance relates to the net credit of £1.2 million to the income statement on the reassessment of future milestone and royalty payments on a licensing agreement.

6. Investments in Associate

(a) Profit/(loss) of Associate

Set out below is the summarised financial information of Medical Ethics Pty Ltd for the year ended 30 June, which is accounted for using the equity method. This is before the elimination of unrealised transactions and adjustments to align to the Group's accounting policies, and is not Dechra Pharmaceuticals PLC's share of the results.

	2023 £m	2022 £m
Revenue	2.1	15.1
Pre-tax (loss)/profit from continuing operations	(3.5)	9.1
Post-tax (loss)/profit from continuing operations	(2.9)	6.2
	2023 £m	2022 £m
Non-current assets	0.2	2.9
Current assets	6.9	11.4
	7.1	14.3
Non-current liabilities	-	-
Current liabilities	(0.5)	(2.5)
	(0.5)	(2.5)
Net assets of associate	6.6	11.8

(b) Interest in Associate

	2023 £m	2022 £m
1 July 2022 and 2021	15.8	17.1
Share of underlying loss after tax	(1.0)	(1.2)
Non-underlying realised profit from continuing operations	0.9	0.6
Share of amortisation of notional intangible asset identified on acquisition (net of tax)	(0.8)	(0.7)
30 June 2023 and 2022	14.9	15.8

The Group holds 49.5% of the issued share capital of Medical Ethics Pty Ltd, which is the holding company of Animal Ethics Pty Ltd. The Group has considered other factors when assessing control, and concluded that it has significant influence but not control of the associate. There is no change in the accounting treatment of the entity from the prior year. The company is incorporated in Australia, which is also the principal place of business. The registered address is c/o Level 3, 649 Bridge Road, Richmond, Victoria 3121, Australia. The company has share capital consisting solely of ordinary shares, which are directly owned by the Group. Medical Ethics Pty Ltd is a private company and there is no quoted market price available for its shares. There are no contingent liabilities relating to the Group's interest in the associate.

The Group's share of the loss arising from its investment in Medical Ethics Pty Ltd includes the effect of harmonising the accounting policies and of amortising the fair value adjustments (net of tax), which are treated as non-underlying. The milestone of AUD1.5 million that was paid to Animal Ethics Pty Ltd in the year relating to the licensing agreement for the global marketing authorisations of Tri-Solfen (excluding Australia and New Zealand) is eliminated in the Group's income statement. The Group's share of this will be realised over the life of the agreement.

Notes to the Consolidated Financial Statements

6. Interests in Associate continued

(c) Reconciliation of Summarised Financial Information Presented to the Carrying Value of Investment in Associate

	2023 £m	2022 £m
Opening interest in associate	3.9	5.2
Share of underlying loss after tax	(1.0)	(1.2)
Non-underlying realised profit from continuing operations	0.9	0.6
Share of amortisation of notional intangible asset identified on acquisition (net of tax)	(0.8)	(0.7)
Interest in associate	3.0	3.9
Goodwill	11.9	11.9
Carrying value of investment in associate	14.9	15.8

7. Profit Before Taxation

The following items have been included in arriving at profit before taxation of continuing operations:

	2023 £m	2022 £m
Cost of inventories recognised as an expense	256.6	236.3
Impairment of inventories included in above figure	12.5	7.3
Depreciation of property, plant and equipment		
– owned assets	9.1	7.2
– right-of-use assets	4.6	3.9
Amortisation of intangible assets	76.0	77.3
Impairment of intangible assets	69.1	2.4
Loss on disposal of leased assets	–	0.7
Loss on disposal of intangible assets	0.1	–
Impairment of receivables	0.3	0.8
Underlying research and development expenditure as incurred	57.5	32.4
Auditors' remuneration	3.0	1.9
Analysis of total fees paid to the Auditors:		
Audit of these financial statements	1.3	0.9
Audit of financial statements of subsidiaries pursuant to legislation	1.2	0.9
Other assurance services – audit related assurance services*	0.5	0.1
Total fees paid to Auditors	3.0	1.9

* This includes £0.1 million (2022: £0.1 million) in relation to the review of the Half-Yearly Report and £0.4 million (2022: £nil) in relation to assurance services in respect of a listing rule requirement arising as a result of the proposed acquisition of the company by Freya Bidco Limited.

8. Employees

The monthly average number of staff employed by the Group during the year, which includes Directors, were:

	2023 Number	2022 Number
Manufacturing	818	686
Distribution	159	147
Sales and administration	1,358	1,203
Total	2,335	2,036

The costs incurred in respect of these employees were:

	2023 £m	2022 £m
Wages and salaries	136.7	108.6
Social security costs	16.5	13.6
Other pension costs	8.3	6.5
Share-based payments charge (see note 26)	2.3	2.9
Total	163.8	131.6

Related party transactions – the remuneration of key management was as follows:

	2023 £m	2022 £m
Short term employee benefits	5.4	6.6
Post-employment benefits	0.3	0.3
Share-based payments charge	1.9	1.5
	7.6	8.4

Key management comprises the Board and the Senior Executive Team. Details of the remuneration, shareholdings, share options and pension contributions of the Executive Directors are included in the Directors' Remuneration Report on pages 152 to 163.

The Group operates a stakeholder personal pension scheme for certain employees and contributed between 3% and 12% of pensionable salaries. The Group also participates in state-run pension arrangements for certain employees in Dechra Veterinary Products SAS and Dechra Veterinary Products B.V.. Total pension contributions amounted to £8.3 million (2022: £6.5 million).

9. Income Taxes

	2023 £m	2022 £m
Current tax – UK corporation tax	0.2	2.2
– overseas tax	23.4	29.7
– adjustment in respect of prior years	0.9	2.8
Total current tax expense	24.5	34.7
Deferred tax – origination and reversal of temporary differences	(30.4)	(15.7)
– adjustment in respect of tax rates	(0.6)	2.2
– adjustment in respect of prior years	(1.7)	(1.8)
Total deferred tax credit	(32.7)	(15.3)
Total income tax (credit)/charge in the Consolidated Income Statement	(8.2)	19.4

Notes to the Consolidated Financial Statements

9. Income Taxes continued

The tax on the Group's profit before taxation differs from the standard rate of UK corporation tax of 20.5% (2022: 19.0%). The differences are explained below:

	2023 £m	2022 £m
(Loss)/profit before taxation	(36.1)	77.6
Tax at 20.5% (2022: 19.0%)	(7.4)	14.7
Effect of:		
– expenses not deductible	3.1	0.8
– research and development related tax credits	(1.2)	(0.2)
– patent box tax credits	(0.7)	(1.5)
– other incentives	(1.3)	(1.6)
– share of results in associates	0.2	0.2
– effects of overseas tax rates	0.5	3.8
– adjustment in respect of prior years	(0.8)	1.0
– change in tax rates	(0.6)	2.2
Total income tax (credit)/charge in the Consolidated Income Statement	(8.2)	19.4

Recurring items in the tax reconciliation include: research and development related tax credits and patent box incentives; expenses not deductible; and the share of results in associates. The effective tax rate is 22.8% (excluding non-underlying items the effective tax rate is 23.1%).

Tax (Charge)/Credit Recognised Directly in Equity

	2023 £m	2022 £m
Deferred tax on other equity movements	(1.1)	(0.4)
Tax charge recognised in Consolidated Statement of Comprehensive Income	(1.1)	(0.4)
Corporation tax on equity settled transactions	–	0.3
Deferred tax on equity settled transactions	(0.2)	(0.7)
Total tax charge recognised in Equity	(0.2)	(0.4)

UK Finance Bill 2021 was substantively enacted on 24 May 2021, including an increase in the main rate of UK corporation tax from 19% to 25%, effective 1 April 2023. The impact of the UK rate change is reflected in the deferred tax balances as at 1 July 2022, based on the Group's best estimate of the timing of unwind of temporary contracts. At 30 June 2023, the Group held a current provision of £5.7 million (2022: £5.9 million) in respect of uncertain tax provisions, comprising a current liability provision of £14.3 million and a current asset of £8.6m. The resolution of these tax matters may take many years. The range of reasonably possible outcomes within the next twelve months is an outflow of £nil to £3.5 million.

EU CFC Challenge

The Group continues to monitor developments in relation to EU State Aid investigations. On 25 April 2019, the EU Commission's final decision regarding its investigation into the UK's Controlled Foreign Company (CFC) regime was published. It concluded that the legislation up until December 2018 does partially represent State Aid. This decision was upheld by the EU General Court on 8 June 2022, when it dismissed the UK Government's annulment application. The UK Government has since lodged an appeal to the EU Court of Justice in August 2022.

At 30 June 2023, the Group considers that the potential amount of additional tax payable is between £nil and £2.75 million (2022: £nil and £4.0 million) depending on the basis of calculation and the outcome of HMRC's appeal to the EU Court of Justice. Based on current advice, the Group does not consider any provision is required in relation to this investigation. This judgement is based on current interpretation of legislation and professional advice.

The Group received charging notices from HMRC in January and February 2021 under The Taxation (Post Transition Period) Act for the full exposure (£2.75 million) and has paid this to HMRC. As the Group considers that HMRC's appeal will be successful, the charging notices which were settled in full during 2021 (£2.75 million) are recorded as current tax receivables on the basis that the amount will be repaid in due course.

Future Tax Charge

The Group's future tax charge, and its effective tax rate could be affected by several factors including the impact of the implementation of the OECD's Base Erosion and Profit Shifting ('BEPS') actions, and changes in applicable tax rates and legislation in the territories in which it operates.

9. Income Taxes continued

OECD Pillar 2

On 20 June 2023, Finance (No.2) Act 2023 was substantively enacted in the UK, introducing a global minimum effective tax rate of 15%. The legislation implements a domestic top-up tax and a multinational top-up tax, effective for accounting periods starting on or after 31 December 2023. The Group has applied the exception under IAS 12 to recognising and disclosing information about deferred tax assets and liabilities related to top-up income taxes. The Group is continuing to assess the potential impact of Pillar 2 on the Group.

10. Dividends

	2023 £m	2022 £m
Final dividend paid in respect of prior year but not recognised as a liability in that year: 32.89 pence per share (2022: 29.39 pence per share)	37.4	31.8
Interim dividend paid: 12.50 pence per share (2022: 12.00 pence per share)	14.3	13.0
Total dividend 45.39 pence per share (2022: 41.39 pence per share) recognised as distributions to equity holders in the year	51.7	44.8
Proposed final dividend for the year ended 30 June 2023: nil per share (2022: 32.89 pence per share)	–	35.6
Total dividend paid and proposed for the year ended 30 June 2023: 12.50 pence per share (2022: 44.89 pence per share)	14.3	48.6

The ongoing acquisition of the Company by Freya Bidco Limited remains conditional upon the receipt of antitrust approval in the European Union and foreign direct investment approval in Australia, in each case to the extent required, as well as the sanction of the Scheme by the Court at the Sanction Hearing (each as defined in the scheme document dated 26 June 2023) and is expected to occur in late 2023 or early 2024. If prior to the acquisition becoming effective, any dividend is announced, declared, made or paid or becomes payable in respect of the ordinary share capital of the Company (Dechra Shares), Freya Bidco Limited reserves the right to reduce the consideration payable under the terms of the acquisition for the Dechra Shares by an amount up to the aggregate amount of such dividend. Therefore the Directors are not recommending the payment of a final dividend. The final dividend for the year ended 30 June 2022 is shown as a deduction from equity in the year ended 30 June 2023.

11. Earnings per Share

Earnings per ordinary share have been calculated by dividing the profit attributable to equity holders of the parent after taxation for each financial year by the weighted average number of ordinary shares in issue during the year.

	2023 Pence	2022 Pence
Basic earnings per share		
– Underlying*	95.09	121.57
– Basic	(24.59)	53.72
Diluted earnings per share		
– Underlying*	94.57	120.84
– Diluted	(24.59)	53.40

* Underlying measures exclude non-underlying items as defined in note 1.

The calculations of basic and diluted earnings per share are based upon:

	2023 £m	2022 £m
Earnings for underlying basic and underlying diluted earnings per share	107.9	131.7
Earnings for basic and diluted earnings per share	(27.9)	58.2

	Number	Number
Weighted average number of ordinary shares for basic earnings per share	113,476,509	108,332,583
Impact of share options	618,369	654,836
Weighted average number of ordinary shares for diluted earnings per share	114,094,878	108,987,419

At 30 June 2023, there are 557,781 options (2022: 305,468) that are excluded from the EPS calculations as they are not dilutive for the period presented but may become dilutive in the future.

Notes to the Consolidated Financial Statements

12. Intangible Assets

	Goodwill £m	Software £m	Development costs £m	Patent rights & marketing authorisations £m	Other intangibles £m	Acquired intangibles £m	Total £m
Cost							
At 1 July 2021	236.1	23.1	15.1	6.5	–	881.3	1,162.1
Additions	–	1.0	1.8	–	–	96.1	98.9
Disposals	–	–	–	(3.3)	–	(0.7)	(4.0)
Transfers between categories	–	0.2	(1.7)	0.4	1.1	–	–
Remeasurement (note 30)	–	–	–	–	–	(24.2)	(24.2)
Foreign exchange adjustments	9.3	0.1	0.2	0.1	0.1	27.4	37.2
At 30 June 2022 and 1 July 2022	245.4	24.4	15.4	3.7	1.2	979.9	1,270.0
Additions	–	0.6	1.6	–	1.3	1.6	5.1
Acquired through Business Combinations	98.7	–	–	–	–	311.0	409.7
Disposals	–	(0.2)	(0.2)	(0.1)	–	–	(0.5)
Transfers between categories	–	0.2	(1.1)	0.9	–	–	–
Remeasurement (note 30)	–	–	–	–	–	(49.6)	(49.6)
Foreign exchange adjustments	(9.6)	–	–	–	(0.1)	(29.4)	(39.1)
At 30 June 2023	334.5	25.0	15.7	4.5	2.4	1,213.5	1,595.6
Accumulated Amortisation							
At 1 July 2021	–	11.2	9.5	4.6	–	421.0	446.3
Charge for the year	–	3.5	0.6	0.4	–	72.8	77.3
Impairments	–	–	–	–	0.7	1.7	2.4
Disposals	–	–	–	(3.4)	–	(0.6)	(4.0)
Foreign exchange adjustments	–	0.1	–	0.1	0.1	17.2	17.5
At 30 June 2022 and 1 July 2022	–	14.8	10.1	1.7	0.8	512.1	539.5
Charge for the year	–	3.6	0.7	0.5	0.1	71.1	76.0
Impairments	–	–	–	–	–	69.1	69.1
Disposals	–	(0.2)	(0.2)	–	–	–	(0.4)
Foreign exchange adjustments	–	–	–	–	–	(11.0)	(11.0)
At 30 June 2023	–	18.2	10.6	2.2	0.9	641.3	673.2
Net book value							
At 30 June 2023	334.5	6.8	5.1	2.3	1.5	572.2	922.4
At 30 June 2022	245.4	9.6	5.3	2.0	0.4	467.8	730.5

£0.8 million of the marketing authorisations relate to the Vetivex® range of products. Ownership of the marketing authorisations rests with the Group in perpetuity. There are not believed to be any legal, regulatory or contractual provisions that limit their useful lives. *Vetivex* is an established range of products which are relatively simple in nature and there are a limited number of players in the market. Accordingly, the Directors believe that it is appropriate that the marketing authorisations are treated as having indefinite lives for accounting purposes.

Goodwill is allocated across cash generating units that are expected to benefit from the relevant business combination. Key assumptions made in this respect are given in note 14.

Included in the cost at 30 June 2023 are £46.9 million (2022: £41.8 million) of fully amortised assets which predominately relate to product rights where sales are still being made by the Group.

12. Intangible Assets continued

In accordance with the disclosure requirements of IAS 38 'Intangible Assets', the components of acquired intangibles are summarised below:

	Commercial relationships £m	Pharmacological process £m	Brand £m	Capitalised development costs £m	Product rights £m	Total £m
Cost	8.1	47.1	14.9	382.4	428.8	881.3
At 1 July 2021	–	–	–	–	96.1	96.1
Additions	–	–	–	–	(24.2)	(24.2)
Remeasurement	–	–	–	–	(0.7)	(0.7)
Foreign exchange adjustments	0.2	6.8	1.8	12.0	6.6	27.4
At 30 June 2022 and 1 July 2022	8.3	53.9	16.7	394.4	506.6	979.9
Additions	–	–	–	0.1	1.5	1.6
Acquisitions through business combinations	–	–	–	–	311.0	311.0
Remeasurement	–	–	–	–	(49.6)	(49.6)
Foreign exchange adjustments	–	(2.4)	(0.6)	(5.0)	(21.4)	(29.4)
At 30 June 2023	8.3	51.5	16.1	389.5	748.1	1,213.5
Accumulated Amortisation						
At 1 July 2021	7.3	35.0	8.4	186.7	183.6	421.0
Charge for the year	1.3	3.6	1.2	37.0	29.7	72.8
Impairments	–	–	–	1.7	–	1.7
Disposals	–	–	–	–	(0.6)	(0.6)
Foreign exchange adjustments	(0.8)	5.3	2.0	5.5	5.2	17.2
At 30 June 2022 and 1 July 2022	7.8	43.9	11.6	230.9	217.9	512.1
Charge for the year	0.5	3.3	1.3	32.4	33.6	71.1
Impairments	–	–	–	–	69.1	69.1
Foreign exchange adjustments	(0.1)	(2.0)	(0.5)	(2.8)	(5.6)	(11.0)
At 30 June 2023	8.2	45.2	12.4	260.5	315.0	641.3
Net book value						
At 30 June 2023	0.1	6.3	3.7	129.0	433.1	572.2
At 30 June 2022	0.5	10.0	5.1	163.5	288.7	467.8

Notes to the Consolidated Financial Statements

12. Intangible Assets continued

The table below provides further detail on the goodwill, acquired intangibles and their remaining amortisation period.

Significant assets	Description of acquired intangibles	Goodwill carrying value £m	Acquired intangibles carrying value £m	Sub-total carrying value £m	Remaining amortisation period on acquired intangibles
Intangible assets arising from the acquisition of Dermapet	Product, marketing and distribution rights	0.4	7.5	7.9	2 ½ years
Intangible assets arising from the acquisition of Eurovet	Technology, product, marketing and distribution rights	37.7	–	37.7	N/A
Goodwill arising from the acquisition of Vetxx		16.4	–	16.4	N/A
Intangible assets arising from the acquisition of Genera	Product, brand, technology, marketing and distribution rights	5.3	0.1 4.5	9.9	2 ½ years 7 ½ years Genera – total
Intangible assets arising from the acquisition of Putney	Product, brand, technology, pharmacological process, marketing and distribution rights	51.7	2.8 6.7 25.7	86.9	3 years 3 years 5 years Putney – total
Intangible assets arising from the acquisition of Apex	Product and technology	8.3	9.1 1.3	18.7	10 years 7 years Apex – total
Intangible assets related to the licensing and distribution of Tri-Solfen® (excluding ANZ territories)	Marketing and distribution rights	–	14.7	14.7	10 years
Intangible asset related to an injectable solution licensing agreement	Marketing and distribution rights	–	5.6	5.6	9 years
Intangible assets arising from the acquisition of AST Farma B.V. and Le Vet Beheer B.V.	Product, brand, technology, marketing and distribution rights	98.7	29.0 32.9 8.8	169.4	4 ½ years 3 ½ years 5 years AST Farma B.V. and Le Vet Beheer B.V. – total
Intangible assets related to an injectable solution licensing agreement	Marketing and distribution rights	–	5.2	5.2	15 years
Intangible assets arising from the acquisition of Caledonian	Product, brand, technology, marketing and distribution rights	0.8	2.0	2.8	5 ½ years

12. Intangible Assets continued

Significant assets	Description	Goodwill carrying value £m	Acquired Intangibles carrying value £m	Sub-total carrying value £m	Remaining amortisation period on acquired intangibles
Intangible assets arising from the acquisition of Dechra Brasil Produtos Veterinarios LTDA	Product, brand, technology, marketing and distribution rights	9.3	5.4 0.1 0.2	15.0	5 ½ years ½ years 3 ½ years Brazil – total
Intangible assets arising from the acquisition of Ampharmco	Product and technology rights	6.4	4.8 0.5 5.2	16.9	14 ½ years 11 ½ years 11 ½ years Ampharmco – total
Intangible assets arising from the acquisition of Mirataz	Product and technology rights	–	28.0 1.4 0.1	29.5	6 ½ years 7 ½ years 7 ½ years Mirataz – total
Intangible assets arising from the acquisition of Osumnia	Product, marketing and distribution rights	–	75.2	75.2	7 years
Intangible assets related to the licensing and distribution of Tri-Solfen® (ANZ territories)	Product, marketing and distribution rights	–	20.5	20.5	13 years
Intangible assets arising from the acquisition of Laverdia	Product, marketing and distribution rights	–	30.6	30.6	10 years
Intangible assets arising from the acquisition of Isoflurane and Sevoflurane	Product, marketing and distribution rights	–	7.6	7.6	8 ½ years
Intangible assets arising from the acquisition of Sucromate	Product, marketing and distribution rights	–	5.4	5.4	8 ½ years
Intangible assets arising from the acquisition of Piedmont Animal Health Inc.	Product rights	40.1	93.6	133.7	21 years
Intangible assets arising from the acquisition of Med-Pharmex Inc.	Product and distribution rights	52.3	123.6	175.9	24 years
Other individually immaterial goodwill and acquired intangibles		7.1	14.1	21.2	
		334.5	572.2	906.7	

Notes to the Consolidated Financial Statements

13. Property, Plant and Equipment

	Freehold land and buildings £m	Short leasehold buildings £m	Motor vehicles £m	Plant and fixtures £m	Total £m
Cost					
At 1 July 2021	54.5	22.2	5.9	57.4	140.0
Additions	5.8	1.6	2.2	14.6	24.2
Disposals	(0.8)	(2.7)	(1.2)	(1.0)	(5.7)
Transfers between categories	1.6	1.1	–	(2.7)	–
Foreign exchange adjustments	0.7	1.2	0.1	1.4	3.4
At 30 June 2022 and 1 July 2022	61.8	23.4	7.0	69.7	161.9
Additions	2.0	1.9	3.7	21.1	28.7
Acquired through Business Combinations	44.2	0.2	–	3.8	48.2
Disposals	(0.6)	(0.7)	(2.1)	(6.0)	(9.4)
Transfers between categories	4.1	(1.4)	–	(2.7)	–
Foreign exchange adjustments	(3.4)	(0.4)	–	(0.9)	(4.7)
At 30 June 2023	108.1	23.0	8.6	85.0	224.7
Accumulated Depreciation					
At 1 July 2021	16.8	7.0	3.1	26.1	53.0
Charge for the year	1.8	2.2	1.9	5.2	11.1
Disposals	(0.8)	(0.7)	(1.1)	(0.9)	(3.5)
Foreign exchange adjustments	0.1	0.3	0.1	0.5	1.0
At 30 June 2022 and 1 July 2022	17.9	8.8	4.0	30.9	61.6
Charge for the year	2.8	2.4	2.5	6.0	13.7
Disposals	(0.5)	(0.6)	(2.6)	(5.5)	(9.2)
Transfers between categories	0.1	(0.1)	–	–	–
Foreign exchange adjustments	(0.1)	(0.2)	–	(0.4)	(0.7)
At 30 June 2023	20.2	10.3	3.9	31.0	65.4
Net book value					
At 30 June 2023	87.9	12.7	4.7	54.0	159.3
At 30 June 2022	43.9	14.6	3.0	38.8	100.3
Net book value of right-of-use assets					
At 30 June 2023	–	11.8	4.7	0.1	16.6
At 30 June 2022	–	12.2	3.1	0.1	15.4
Depreciation charge of right-of-use assets					
2023	–	2.1	2.5	–	4.6
2022	–	1.9	1.9	0.1	3.9
				2023	2022
				£m	£m
Contracted capital commitments				5.1	6.0
Assets in the course of construction included above				14.9	5.3

Included in additions are £5.6 million (2022: £3.8 million) of right-of-use assets.

Included in the cost at 30 June 2023 are £61.3 million (2022: £52.7 million) of fully depreciated assets.

14. Impairment Reviews

Goodwill and indefinite life asset Impairment Assessment

Goodwill and indefinite life assets are tested for impairment annually, or more frequently if there are indications that amounts might be impaired. The impairment tests involve determining the recoverable amount of the relevant asset or cash generating unit ('CGU'), which corresponds to the higher of the fair value less costs to sell or its value in use. In the Group's case, the recoverable amount is based on value in use calculations.

Goodwill is tested for impairment at the operating segment level, this being the level at which goodwill is monitored for internal management purposes. An immaterial quantum of intangible assets which have an indefinite life are also allocated with goodwill as follows:

	2023			
Cash generating unit	Goodwill carrying value £m	Indefinite life assets carrying value £m	Total value £m	Pre-tax discount rate %
Dechra Veterinary Products EU	162.2	0.9	163.1	11.5
Dechra Veterinary Products NA	153.9	–	153.9	12.2
Dechra Veterinary Products International	18.4	–	18.4	16.0
	334.5	0.9	335.4	

	2022			
Cash generating unit	Goodwill carrying value £m	Indefinite life assets carrying value £m	Total value £m	Pre-tax discount rate %
Dechra Veterinary Products EU	162.2	0.9	163.1	10.2
Dechra Veterinary Products NA	64.3	–	64.3	12.0
Dechra Veterinary Products International	18.9	–	18.9	13.1
	245.4	0.9	246.3	

The recoverable amount of each CGU is determined using value in use calculations with the key assumptions being as follows:

- The latest available Board approved business plan for the first two years;
- The business plan is extrapolated by applying a growth rate for years three, four and five of 3.0% (2022: 3.0%) for Dechra Veterinary Products EU and Dechra Veterinary Products NA and 6.8% (2022: 6.6%) for Dechra Veterinary Products International; and
- Thereafter, a terminal value is calculated based on year five cash flows, and assuming a long term growth rate of 0% (2022: 0%) for Dechra Veterinary Products EU and Dechra Veterinary Products NA and 1.3% (2022: 1.2%) for Dechra Veterinary Products International.

The projections covered a period of five years as the Directors believe this to be the most appropriate timescale over which to review and consider annual performances before applying a fixed terminal value.

The Board approved business plan incorporates a number of key input assumptions, most notably regarding market growth expectations, the competitive and legislative environments, lifecycle management, selling prices, product margins and direct costs. The assumptions applied in the business plan are based on past experience and the Group's expectation of future market changes and, where applicable, are consistent with external sources of information.

The medium and long term growth rates used (as set out above) reflect an estimate of expected future growth in the Group's markets and are no higher than those implicit in the Group's strategic planning process, and do not exceed the long term growth rates in the countries in which each CGU operates.

The pre-tax discount rates have been estimated using a market participant rate, which is risk adjusted dependent upon the specific circumstances of each asset or CGU.

Sensitivity analyses have been performed around the key assumptions for the impairment testing of goodwill and indefinite life assets with the conclusion for both being that given the headroom in each CGU, no reasonable changes in key assumptions would cause the recoverable amount to be materially less than the carrying value.

Notes to the Consolidated Financial Statements

14. Impairment Reviews continued

Intangible assets under development and not available for use Impairment assessment

Intangible assets under development and not available for use (typically In-Process Research and Development ('IPR&D')) are tested for impairment annually.

In 2023, the impairment charges recorded against NA Pharmaceuticals IPR&D, totalled £69.1 million and related to IPR&D recognised as part of the acquisition of Piedmont Animal Health Inc. Assets in respect of one near term candidate product within the pipeline was fully impaired following a reduction in the likelihood of success of this product. The recoverable amount of the asset was valued based on fair value less costs of disposal using the multi-period excess earnings method, and was categorised at Level 3 in the fair value hierarchy. The key assumptions in the valuation being the probability of success of the product (0%).

The key assumptions for the remainder of the IPR&D intangible assets which have been valued on a combination of both the multi-period excess earnings method and the replacement cost method are; (a) Post-tax discount rates (10.75% - 11.25%); (b) forecasted cash flows based on Board approved business plan; (c) 30% volume attrition upon patent expiry; and (d) 5% volume attrition post patent expiry.

The table below shows on an indicative basis the sensitivity to reasonably possible changes in significant assumptions used in the valuation of the intangible assets;

	Intangible assets
1% increase in discount rates (£m)	(11.2)
1% decrease in discount rates (£m)	13.3
10% increase in cash flows (£m)	11.3
10% decrease in cash flows (£m)	(11.3)
5% increase in ongoing volume attrition (£m)	(5.8)
5% decrease in ongoing volume attrition (£m)	12.5

Other intangible asset impairment assessment

Other intangible assets are tested when there is a trigger of impairment loss or reversal. Where testing is required, the recoverable amount of the assets is estimated in order to determine the extent of the impairment loss or reversal. Where it is not possible to estimate the recoverable amount of an individual asset, the Group estimates the recoverable amount of the CGU to which it belongs. The CGUs for the purposes of this assessment are deemed to be countries or clusters of countries. During the year a trigger was identified in two CGUs. No impairment was identified and there is no reasonable change in key assumptions underpinning these assessments that would cause a material impairment.

We have assessed the qualitative and quantitative impact of climate related risks on asset recoverable amounts and concluded that their impact does not have a material impact on the Group's impairment assessments performed.

15. Deferred Taxes

(a) Recognised Deferred Tax Assets and Liabilities

Deferred tax assets and liabilities are analysed in the statement of financial position after offset, to the extent there is a legally enforceable right, of balances within countries as follows:

	2023 £m	2022 £m
Deferred tax assets	4.9	2.3
Deferred tax liabilities	(76.3)	(35.8)
	(71.4)	(33.5)

Deferred tax assets and liabilities are attributable to the following, prior to any allowable offset:

	Assets		Liabilities		Net	
	2023 £m	2022 £m	2023 £m	2022 £m	2023 £m	2022 £m
Intangible assets	–	–	(88.5)	(42.9)	(88.5)	(42.9)
Property, plant and equipment	–	–	(10.7)	(4.8)	(10.7)	(4.8)
Inventories	2.8	1.5	–	–	2.8	1.5
Receivables/payables	6.6	7.2	–	–	6.6	7.2
Share-based payments	1.0	0.9	–	–	1.0	0.9
Losses	8.1	0.6	–	–	8.1	0.6
R&D tax credits	8.5	3.0	–	–	8.5	3.0
Employee benefit obligations	0.1	1.0	–	–	0.1	1.0
Interest	0.7	–	–	–	0.7	–
	27.8	14.2	(99.2)	(47.7)	(71.4)	(33.5)

(b) Unrecognised Deferred Tax

The aggregate amount of gross temporary differences associated with investments in subsidiaries for which deferred tax liabilities have not been recognised is £108.4 million (2022: £2.2 million). The estimated unprovided deferred tax liability in relation to these temporary differences is £5.4 million (2022: £0.1 million). No deferred tax liability has been recognised in respect of unremitted earnings of subsidiaries because the Group is able to control the timing of the reversal of the temporary difference, and it is probable that such differences will not reverse in the foreseeable future. The increase in the unrecognised deferred tax liability arises as a result of the pending acquisition of the Group by Freya Bidco Limited which would mean that, as a non-listed group, withholding tax at a rate of 5% would likely be suffered on dividends paid by the Group's US business.

Deferred tax assets in relation to losses amounting to £1.5 million (2022: £2.6 million) have not been recognised due to uncertainty over their recoverability. Included within unrecognised losses are £0.5 million of losses which expire prior to 2030. Other losses may be carried forward indefinitely.

Notes to the Consolidated Financial Statements

15. Deferred Taxes continued (c) Movements During the Year

	Balance at 1 July 2021 £m	Recognised in income £m	Recognised in equity/OCI £m	Foreign exchange adjustments £m	Balance at 30 June 2022 £m
Intangible assets	(51.1)	9.9	–	(1.6)	(42.8)
Property, plant and equipment	(3.7)	(1.0)	–	(0.1)	(4.8)
Inventories	0.9	0.6	–	–	1.5
Receivables/payables	4.1	2.9	(0.4)	0.6	7.2
Share-based payments	1.7	(0.1)	(0.7)	–	0.9
Losses	0.7	(0.2)	–	0.1	0.6
R&D tax credits	0.5	2.4	–	0.1	3.0
Employee benefit obligations	0.1	0.8	–	–	0.9
	(46.8)	15.3	(1.1)	(0.9)	(33.5)

	Balance at 1 July 2022 £m	Recognised in income £m	Recognised in equity/OCI £m	Foreign exchange adjustments £m	Acquisitions through business combinations £m	Balance at 30 June 2023 £m
Intangible assets	(42.8)	27.9	–	4.1	(77.7)	(88.5)
Property, plant and equipment	(4.8)	1.2	–	0.6	(7.7)	(10.7)
Inventories	1.5	1.8	–	(0.1)	(0.4)	2.8
Receivables/payables	7.2	(0.7)	(1.1)	–	1.2	6.6
Share-based payments	0.9	–	(0.2)	0.3	–	1.0
Losses	0.6	(1.5)	–	(0.5)	9.5	8.1
R&D tax credits	3.0	4.2	–	(0.1)	1.4	8.5
Employee benefit obligations	0.9	(0.9)	–	0.1	–	0.1
Interest	–	0.7	–	–	–	0.7
	(33.5)	32.7	(1.3)	4.4	(73.7)	(71.4)

16. Inventories

	2023 £m	2022 £m
Raw materials and consumables	58.7	38.0
Work in progress	10.0	10.1
Finished goods and goods for resale	148.6	127.6
	217.3	175.7

17. Trade and Other Receivables

	2023 £m	2022 £m
Trade receivables	144.2	122.1
Other receivables	11.1	9.0
Prepayments and accrued income	6.6	5.7
	161.9	136.8

Trade receivables are presented net of a loss allowance to reflect the expected credit losses. The details of this allowance for credit losses are disclosed in note 24.

18. Cash and Cash Equivalents

	2023 £m	2022 £m
Cash at bank and in hand	74.4	120.9

19. Trade and Other Payables

	2023 £m	2022 £m
Trade payables	43.4	46.0
Other payables	2.3	3.1
Other taxation and social security	10.1	4.6
Accruals	88.7	83.1
	144.5	136.8

20. Current Tax Assets and Liabilities

	2023 £m	2022 £m
Corporation tax receivable	14.3	11.0
Corporation tax payable	(11.5)	(12.2)
	2.8	(1.2)

21. Borrowings and Lease Liabilities

	2023 £m	2022 £m
Current liabilities:		
Lease liabilities	3.9	3.3
	3.9	3.3
Non-current liabilities:		
Lease liabilities	13.0	12.1
Senior loan notes	250.7	125.5
Bank loans	241.3	189.7
Arrangement fees netted off	(4.4)	(1.5)
	500.6	325.8
Total borrowings	504.5	329.1

On 31 March 2023, the Group entered into a new multi-currency Revolving Credit Facility Agreement (“RCF”) with a maximum amount of £340.0 million and maturing 31 March 2028. This RCF is provided by a syndicate of banks comprising BNP Paribas, CaixaBank SA UK branch, Crédit Industriel et Commercial, London Branch, Handelsbanken Capital Markets, Handelsbanken plc, HSBC UK Bank plc, PNC Capital Markets LLC, Santander UK plc and The Governor and Company of the Bank of Ireland. The covenant requirements in the RCF remain unchanged from the prior Revolving Credit Facility Agreement (being Interest Cover in respect of any Relevant Period shall not be less than 4:1 and Leverage in respect of any Relevant Period shall not exceed 3:1).

The RCF uses Risk Free Reference (RFR) rates, with the relevant RFR rates for the principal Borrowings of the Group being SONIA (for Borrowings in GBP), SOFR (for Borrowings in USD) and EURIBOR (for Borrowings in EUR). The interest rate charged on any new Borrowings drawn under the RCF will be the relevant RFR rate plus the Margin. The Margin on the RCF is a minimum of 1.40% and a maximum of 2.30%, dependent upon the Leverage (the ratio of Adjusted Net Debt to Adjusted underlying EBITDA) of the Group. At 30 June 2023, £241.3 million was drawn against the £340.0 million RCF. The facility is not secured on any specific assets of the Group but is supported by a joint and several cross guarantee structure. All covenants were met during the year ended 30 June 2023.

Notes to the Consolidated Financial Statements

21. Borrowings and Lease Liabilities continued

In January 2020, the Group undertook a Private Placement raising EUR50.0 million and USD100.0 million (under seven and ten year new senior secured notes respectively) which remains fully drawn at 30 June 2023. The Private Placement amounts are not secured on any specific assets of the Group, but are supported by a joint and several cross guarantee structure. Interest is charged on the EUR50.0 million amount at a fixed rate of 1.19% until maturity (January 2027). Interest is charged on the USD100.0 million amount at a fixed rate of 3.34% until maturity (January 2030).

On 14 July 2022 the Group undertook a further Private Placement raising EUR50.0 million and EUR100.0 million (under seven and ten year new senior secured notes respectively), the proceeds of which were used to repay existing debt. Both facilities remain fully drawn at 30 June 2023. Interest is charged on the EUR50.0 million senior secured notes at a fixed rate of 3.64% until maturity (July 2029), and on the EUR100.0 million senior secured notes at a fixed rate of 3.93% until maturity (July 2032).

No interest has been capitalised during the year (2022: £nil).

The maturity of the bank loans and senior loan notes is as follows:

	2023 £m	2022 £m
Between two and five years	284.3	232.6
Over five years	207.7	82.6
	492.0	315.2

The maturity of the lease liabilities is as follows:

	2023 £m	2022 £m
Within one year	3.9	3.3
Between one and two years	3.2	2.5
Between two and five years	4.4	3.5
Over five years	5.4	6.1
	16.9	15.4

Further information on the interest profile of borrowings is shown in note 24.

22. Provisions

	Deferred Rent £m	Provision for PPE grant £m	Dilapidations £m	Total £m
At 1 July 2022	(0.3)	(0.6)	(1.3)	(2.2)
Provision released	–	–	0.5	0.5
Provision utilised	0.1	–	–	0.1
Foreign exchange differences	–	(0.1)	–	(0.1)
At 30 June 2023	(0.2)	(0.7)	(0.8)	(1.7)
	Deferred Rent £m	Provision for PPE grant £m	Dilapidations £m	Total £m
At 1 July 2021	(0.3)	(0.9)	(2.3)	(3.5)
Provision released	–	–	1.0	1.0
Provision utilised	0.1	0.1	–	0.2
Foreign exchange differences	(0.1)	0.2	–	0.1
At 30 June 2022	(0.3)	(0.6)	(1.3)	(2.2)

22. Provisions continued

The Group has received advanced payment for rental income on its facilities in Portland. This has been recognised at amortised cost and is being utilised over the period of the rental contract expiring in January 2025.

Genera, the manufacturing site in Croatia, has received advanced funding (PPE grant) for the refurbishment of the manufacturing facility for a third party manufacturing contract. The funding has been recognised at amortised cost and is being utilised over the life of the property, plant and equipment until 2025.

On the acquisition of Ampharmco, the Group established a fair value provision of £0.5 million for dilapidations of a warehouse property. This has been fully released in the year through non-underlying expenses.

In the financial year 2021, the Group established a fair value provision of £0.8 million for dilapidations of a warehouse property in Skipton in line with IFRS 16. The provision for the remaining warehouse will be utilised over the period to the expiry of the lease in March 2025.

23. Employee Benefit Obligations

Jubilee awards in Netherlands, Germany and Croatia of £0.2 million (2022: £0.3 million) for employees are recognised within other payables in the Consolidated Statement of Financial Position as at 30 June 2023.

24. Financial Instruments and Related Disclosures

The Group's financial instruments comprise private placements, bank loans and overdrafts, lease liabilities, derivatives used for hedging purposes and trade receivables and payables.

Treasury Policy

The Group reports in Sterling and pays dividends in Sterling out of the Group profits which are repatriated to Dechra Pharmaceuticals PLC from subsidiary companies through dividends. The role of the Group's treasury activities is to manage and monitor the Group's global cash resources, to manage external and internal funding requirements and to manage financing risks in support of the Group's corporate activities.

The Board of Directors has approved a Treasury policy which governs all treasury activities.

The Group uses a variety of financial instruments, including derivatives, to finance its operations and to manage market risks from these operations. Derivatives, principally comprising forward foreign currency contracts, foreign currency options and interest rate swaps, are used to hedge against changes in foreign currencies and interest rates. Hedges of net investments in foreign operations are also used in the management of foreign currency risk.

The Group does not hold or issue derivative financial instruments for speculative purposes and the Group's treasury policy specifically prohibits such activity. All transactions in financial instruments are undertaken to manage the risks arising from underlying business activities, not for speculation.

The Group actively manages its exposure to credit risk, reducing surplus cash balances wherever possible. This is part of the strategy to concentrate cash centrally as much as possible. The table below sets out the credit exposure to counterparties by rating for liquid investments, cash and cash equivalents and derivatives.

Credit ratings are assigned to our bank counterparties by Standard and Poor's and Moody's respectively. Where the opinions of the rating agencies differ, the Group assigns the lower rating to the counterparty. Where local rating agency or Fitch data is the only source available, the ratings are converted to global ratings equivalent to those of Standard and Poor's or Moody's using published conversion tables. These credit ratings form the basis of the assessment of the expected credit loss on treasury-related balances held at amortised cost, being bank balances and deposits.

	2023 £m	2022 £m
AA/Aa	48.2	16.4
A/A	21.9	101.1
BBB/Baa	3.4	2.4
BB/Ba and below/unrated	0.9	1.0
Total bank balances and deposits	74.4	120.9

The Group measures expected credit losses over cash and cash equivalents as a function of individual counterparty credit ratings and associated 12 month default rates. Expected credit losses over cash and cash equivalents are deemed to be immaterial and no such loss has been experienced during 2023.

Notes to the Consolidated Financial Statements

24. Financial Instruments and Related Disclosures continued

Capital Management

The capital structure of the Group consists of net borrowings and shareholders' equity. At 30 June 2023, net borrowing was £430.1 million (2022: £208.2 million), whilst shareholders' equity was £755.2 million (2022: £666.8 million).

The Group maintains a strong capital base so as to maintain investors', creditors' and market confidence and to sustain future development of the business.

The Group manages its capital structure to maintain a prudent balance between debt and equity that allows sufficient headroom to finance the Group's product development programme and appropriate acquisitions. There were no changes in the Group's approach to capital management during the year.

The Group operates globally, primarily through subsidiary companies established in the markets in which the Group trades. The Group's operating subsidiaries are generally cash generative and none are subject to externally imposed capital requirements.

There are financial covenants associated with the Group's borrowings, which are interest cover (the ratio of Adjusted underlying EBITDA to Net Finance Charges), and leverage (the ratio of Adjusted Net Debt to Adjusted underlying EBITDA). The Group complied with these covenants in the Years to 30 June 2023 and 2022 and is forecast to continue to do so in the future.

Operating cash flow is used to fund investment in the development of new products as well as to meet the routine outflows of capital expenditure, tax, dividends and repayment of maturing debt.

The Group's policy is to maintain borrowing facilities centrally which are then used to finance the Group's operating subsidiaries, either by way of equity investments or intercompany loans.

Financial Risk Management

The Group has exposure to the following risks from its use of financial instruments:

- liquidity risk;
- market risk; and
- credit risk.

This note presents information about the Group's exposure to each of the above risks, and the Group's objectives, policies and processes for measuring and managing risk.

Liquidity Risk

Liquidity risk is the risk that the Group will not have sufficient funds to meet liabilities as they fall due. Cash flows and covenants of the Group are monitored half-yearly. These are reviewed to ensure that sufficient financial headroom exists for at least a 12 month period. Please refer to Note (1b) for more detail on the Directors' considerations in respect of going concern, including reference to the material uncertainty that exists due to the proposed acquisition by Freya Bidco Limited.

The Group manages its funding requirements through the following lines of credit:

- £340.0 million multi-currency revolving credit facility;
- Private Placements in the amounts of USD100.0 million and EUR200.0 million; and
- £16.9 million lease liabilities.

The Group's borrowing facilities at 30 June 2023 are detailed in note 21.

Market Risk

Market risk is the risk that changes in market prices, such as interest rates or foreign exchange rates, will affect the Group's income or the value of its holding of financial instruments.

Interest Rate Risk Management

The Group's borrowings bear interest at both floating rates linked to Risk Free Reference rates and fixed rates, thereby reducing the exposure to cash flow interest rate risk.

Foreign Exchange Risk Management

Foreign currency transaction exposure arising on normal trade flows is not hedged. The Group matches receipts and payments in the relevant foreign currencies as far as practicable. To this end, bank accounts are maintained for all the major currencies in which the Group trades. Translational exposure in converting the income statements of foreign subsidiaries into the Group's presentational currency of Sterling is not hedged.

The Group hedges selectively expected currency cash flows outside normal trading activities. The Group has designated a US Dollar borrowing of \$357.0 million as a net investment hedge of US Dollar net assets.

24. Financial Instruments and Related Disclosures continued

Credit Risk

Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to meet its contractual obligations.

The Group considers its maximum credit risk to be £155.3 million (2022: £131.1 million), which is the total carrying value of the Group's financial assets excluding cash and cash equivalents.

Our principal customers are pharmaceutical wholesalers and distributors. The failure of a large wholesaler could have a material adverse impact on the Group's financial results.

Two customers of the Group individually accounted for more than 10% of total Group revenues (2022: two). These customers sit within the NA Pharmaceuticals segment and accounted for approximately 28.2% and 11.5% of gross trade receivables at 30 June 2023 (2022: 25.5% and 15.2%). These customers also accounted for 20.9% and 13.2% of total Group revenues (2022: 21.2% and 13.7%).

All new customers are subject to a credit vetting process and existing customers will be subject to a review periodically. The vetting process and subsequent reviews involve obtaining information including audited financial statements, credit bureau reports, debt rating agency (e.g. Moody's, Standard & Poor's) reports and bank references.

Trade receivables consist mostly of amounts due from a large number of customers, spread across geographical areas. Ongoing credit evaluation is performed on the financial condition of accounts receivable.

The amount of information obtained is proportional to the level of exposure being considered. The information is evaluated quantitatively (i.e. credit score) and qualitatively (i.e. judgement) in conjunction with the customer's credit requirements to determine a credit limit.

Trade receivables are written off when there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, amongst others, the failure of a debtor to engage in a repayment plan with the Group.

Fair Value of Financial Assets and Liabilities

The following table presents the carrying amounts and the fair values of the Group's financial assets and liabilities at 30 June 2023 and 30 June 2022. The following assumptions were used to estimate the fair values:

- Cash and cash equivalents – approximated to the carrying amount.
- Derivatives (interest rate swaps) – based upon the amount that the Group would receive or pay to terminate the instrument at the balance sheet date, being the market price of the instrument.
- Receivables and payables – approximated to the carrying amount.
- Borrowings, bank loans and overdrafts – based upon discounted cash flows using discount rates based upon facility rates.

Notes to the Consolidated Financial Statements

24. Financial Instruments and Related Disclosures continued

Analysis of Financial Instruments

The financial instruments of the Group measured at amortised cost are analysed as follows:

	2023		2022	
	Carrying value £m	Fair value £m	Carrying value £m	Fair value £m
Financial assets				
Financial assets measured at amortised cost				
– cash and cash equivalents	74.4	74.4	120.9	120.9
– trade receivables	144.2	144.2	122.1	122.1
– other receivables	11.1	11.1	9.0	9.0
Total financial assets	229.7	229.7	252.0	252.0
Financial liabilities				
Bank loans and overdrafts	(241.3)	(241.3)	(189.7)	(189.7)
Senior loan notes	(250.7)	(234.4)	(125.5)	(115.2)
Lease liabilities	(16.9)	(16.9)	(15.4)	(15.4)
Trade payables	(43.4)	(43.4)	(46.0)	(46.0)
Other payables	(2.3)	(2.3)	(3.1)	(3.1)
Accruals	(88.7)	(88.7)	(83.1)	(83.1)
Contingent consideration	(75.7)	(75.7)	(110.4)	(110.4)
Total financial liabilities	(719.0)	(702.7)	(573.2)	(562.9)
Net financial liabilities	(489.3)	(473.0)	(321.2)	(310.9)

Senior loan notes are carried at amortised cost. Amounts denominated in foreign currencies are valued at the exchange rate prevailing at the balance sheet date. The fair value of borrowings is estimated by discounting contractual future cash flows (Level 2 as defined by IFRS 13).

Fair Value Hierarchy

The table below analyses the Group's financial instruments carried at fair value, by valuation method. Where possible, quoted prices in active markets are used (Level 1). Where such prices are not available, the asset or liability is classified as Level 2, provided all significant inputs to the valuation model used are based on observable market data. If one or more of the significant inputs to the valuation model is not based on observable market data, the instrument is classified as Level 3. There were no transfers between Level 1 and Level 2 during the year.

	Level 1 £m	Level 2 £m	Level 3 £m	Total £m
30 June 2023				
Contingent consideration	–	–	(75.7)	(75.7)
Total	–	–	(75.7)	(75.7)
	Level 1 £m	Level 2 £m	Level 3 £m	Total £m
30 June 2022				
Contingent consideration	–	–	(110.4)	(110.4)
Total	–	–	(110.4)	(110.4)

Contingent consideration is recorded at fair value based on risk-adjusted future cash flows discounted using appropriate interest rates, which are reviewed annually. The inputs relating to future cash flows will include cash flows relating to the relevant contractual arrangements. Refer to note 5 for amounts recognised in the Consolidated Income Statement in the year. Quantified information about significant unobservable inputs is disclosed within note 30.

Credit Risk

The Group applies the IFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables. There has been no change in the estimation techniques or significant assumptions made during the current year in assessing the loss allowance for financial assets at amortised cost.

To measure the expected credit losses, trade receivables have been grouped based on shared credit risk characteristics, and the days past due. The expected loss rates are based on the payment profiles of sales over a period of 36 months before 30 June 2023 and the corresponding historical losses experienced within this period. The historical loss rates are adjusted to reflect current and forward looking information on macroeconomic factors affecting the ability of the customers to settle the receivables.

24. Financial Instruments and Related Disclosures continued

The loss allowance provision as at 30 June 2023 and 30 June 2022 is determined as follows:

30 June 2023	Not due £m	Past due (up to one month) £m	Past due (one to three months) £m	Past due (over three months) £m	Total £m
Expected loss rate	0.02%	0.02%	0.02%	75%	
Gross carrying amount – trade receivables	137.9	4.8	1.2	1.6	145.5
Loss allowance	–	–	–	0.3	0.3
Specific loss allowance	–	0.1	–	0.9	1.0
Total loss allowance	–	0.1	–	1.2	1.3

30 June 2022	Not due £m	Past due (up to one month) £m	Past due (one to three months) £m	Past due (over three months) £m	Total £m
Expected loss rate	0.03%	0.03%	0.03%	75.0%	
Gross carrying amount – trade receivables	116.0	4.1	1.8	1.2	123.1
Loss allowance	–	–	–	0.3	0.3
Specific loss allowance	–	–	–	0.7	0.7
Total loss allowance	–	–	–	1.0	1.0

The movement in the loss allowances for trade debtors at 30 June 2023 reconciles to the opening loss allowances as follows:

	2023 £m	2022 £m
At start of Year	1.0	0.7
Impairment provision recognised	0.3	0.8
Impairment provision utilised	–	(0.5)
At end of Year	1.3	1.0

Liquidity Risk – Contracted Cash Flows of Financial Liabilities

The following table shows the cash flow commitments of the Group in respect of financial liabilities at 30 June 2023 and 30 June 2022. Where interest is at floating rates, the future interest payments have been estimated using current interest rates:

At 30 June 2023	Contingent consideration £m	Bank loans and senior loan notes £m	Lease liabilities £m	Trade, other payables and accruals £m	Total £m
Carrying value	(75.7)	(487.6)	(16.9)	(134.4)	(714.6)
Arrangement fees netted off	–	(4.4)	–	–	(4.4)
Future interest	(52.1)	(6.8)	(2.1)	–	(61.0)
Total committed cash flow	(127.8)	(498.8)	(19.0)	(134.4)	(780.0)
Payable:					
Within 6 months	(1.4)	(6.8)	(2.2)	(120.5)	(130.9)
Between 6 months and 1 year	(3.1)	–	(2.1)	(13.0)	(18.2)
Between 1 and 2 years	(8.7)	–	(3.6)	(0.3)	(12.6)
Between 2 and 3 years	(24.4)	–	(3.1)	–	(27.5)
Between 3 and 4 years	(13.0)	(42.9)	(1.4)	–	(57.3)
Between 4 and 5 years	(7.5)	(241.4)	(1.1)	–	(250.0)
Over 5 years	(69.7)	(207.7)	(5.5)	(0.6)	(283.5)
	(127.8)	(498.8)	(19.0)	(134.4)	(780.0)

Notes to the Consolidated Financial Statements

24. Financial Instruments and Related Disclosures continued

At 30 June 2022	Contingent consideration £m	Bank loans and senior loan notes £m	Lease liabilities £m	Trade, other payables and accruals £m	Total £m
Carrying value	(110.4)	(313.7)	(15.4)	(132.2)	(571.7)
Arrangement fees netted off	–	(1.5)	–	–	(1.5)
Future interest	(65.1)	(2.1)	(1.9)	–	(69.1)
Total committed cash flow	(175.5)	(317.3)	(17.3)	(132.2)	(642.3)
Payable:					
Within 6 months	(3.3)	(2.1)	(1.9)	(119.6)	(126.9)
Between 6 months and 1 year	(3.6)	–	(1.8)	(11.9)	(17.3)
Between 1 and 2 years	(7.6)	–	(2.8)	–	(10.4)
Between 2 and 3 years	(32.0)	(189.7)	(2.1)	(0.2)	(224.0)
Between 3 and 4 years	(16.8)	–	(1.4)	(0.1)	(18.3)
Between 4 and 5 years	(14.7)	(42.9)	(1.1)	–	(58.7)
Over 5 years	(97.5)	(82.6)	(6.2)	(0.4)	(186.7)
	(175.5)	(317.3)	(17.3)	(132.2)	(642.3)

Foreign Currency Exposure

The Sterling equivalents of financial assets and liabilities denominated in foreign currencies at 30 June 2023 and 30 June 2022 were:

	Australian Dollar £m	Danish Krone £m	Euro £m	US Dollar £m	Other £m
At 30 June 2023					
Financial assets					
Trade receivables	–	–	7.2	0.3	2.9
Other receivables	–	–	–	0.1	–
Cash balances	6.2	0.5	28.8	2.4	11.8
	6.2	0.5	36.0	2.8	14.7
Financial liabilities					
Bank loans and overdrafts	–	–	(171.7)	(284.4)	–
Lease liabilities	–	–	–	–	–
Trade payables	(1.5)	–	(5.3)	(1.6)	(0.2)
Other payables	–	–	–	–	–
Accruals	(0.7)	–	(3.4)	(2.5)	(1.7)
Contingent consideration	(23.9)	–	(1.7)	(45.2)	–
	(26.1)	–	(182.1)	(333.7)	(1.9)
Net balance sheet exposure	(19.9)	0.5	(146.1)	(330.9)	12.8
At 30 June 2022					
Financial assets					
Trade receivables	–	–	8.9	0.6	0.3
Other receivables	–	–	1.0	0.5	0.2
Cash balances	5.8	–	50.2	19.2	12.2
	5.8	–	60.1	20.3	12.7
Financial liabilities					
Bank loans and overdrafts	–	–	(42.9)	(82.6)	–
Lease liabilities	–	–	(0.3)	–	–
Trade payables	(0.2)	–	(5.2)	(0.9)	(0.2)
Other payables	–	–	–	–	–
Accruals	–	–	(2.1)	(1.3)	(1.3)
Contingent consideration	(34.5)	–	(1.9)	(73.2)	–
	(34.7)	–	(52.4)	(158.0)	(1.5)
Net balance sheet exposure	(28.9)	–	7.7	(137.7)	11.2

24. Financial Instruments and Related Disclosures continued

Sensitivity Analysis

Interest Rate Risk

A 2.0% increase in annual interest rates compared to those ruling at 30 June 2023 would increase Group loss before taxation and equity by £4.4 million (2022: £3.8 million).

Foreign Currency Risk

The Group has significant cash flows and net financial assets and liabilities in US Dollar, Euro, Danish Krone and Australian Dollar. The Group does not hedge either economic exposure or the translation exposure arising from the profits of non-Sterling businesses. The Group is hedging certain foreign currency translations through the designation of a US Dollar loan as a net investment hedge of US Dollar net assets.

During 2023, the Group has been exposed to transactional and translational currency risk. In addition to the transactional gain of £2.2 million (2022: £4.5 million transactional loss) being recognised in the Consolidated Income Statement, £15.0 million foreign exchange loss (2022: £15.7 million foreign exchange gain) translational impact was recognised in the Consolidated Statement of Comprehensive Income in the year.

As part of its acquisition strategy, the Group seeks to balance the foreign exchange debt and related interest payable risk associated with non-Sterling acquisitions with the underlying related income and assets in foreign currencies.

The following table shows the impact on the Group's profit after taxation of a 10% appreciation of Sterling against each of these currencies compared to the rates prevailing at the year end date. In this analysis, only financial assets and liabilities held on the balance sheet at the year end are assessed and are only considered sensitive to foreign exchange rates where they are not in the functional currency of the entity that holds them. There is no impact on other equity reserves.

	Profit after taxation £m
Australian Dollar	(1.8)
Euro	(12.9)
US Dollar	(22.5)

The sensitivities on the above represent the Directors' view of reasonably possible changes in each risk variable, not worst case scenarios or stress tests. The outputs from the sensitivity analysis are estimates of the impact of the effect of changes in market risks assuming that the specified changes occur at the year end and are applied to the risk exposures at that date. Accordingly, they show the impact on profitability and the balance sheet from such movements.

Actual results in the future may differ materially from these estimates due to commercial actions taken to mitigate any potential losses from such rate movements, to the interaction of more than one sensitivity occurring and to further developments in global financial markets. As such, this table should not be considered as a projection of likely future gains and losses.

25. Issued Share Capital

	Ordinary shares of 1 pence each			
	2023		2022	
	£m	Number	£m	Number
Allotted, called up and fully paid at start of year	1.1	108,392,737	1.1	108,215,323
New shares issued	–	5,495,453	–	177,414
Allotted, called up and fully paid at end of year	1.1	113,888,190	1.1	108,392,737

The Companies Act 2006 abolishes the requirement for a company to have an authorised share capital. At the 2009 Annual General Meeting, the shareholders approved a resolution whereby all provisions relating to the Company's authorised share capital were removed from the Company's constitutional documents.

During the year, 130,770 new ordinary shares of 1 pence each (2022: 177,414 new ordinary shares of 1 pence each) were issued following the exercise of options under the Long Term Incentive Plan, the Approved, the Unapproved, SAYE, the Global SAYE and the ESPP share option schemes. The consideration received was £1,845,278 (2022: £2,258,853). The holders of ordinary shares are entitled to receive dividends as declared or approved at General Meetings from time to time and are entitled to one vote per share at such meetings of the Company.

The Company issued 5,247,813 shares of 1 pence each by way of a placing and 116,870 ordinary shares via a retail offer, both at an issue price of 3430 pence per share on 25 July 2022. The placing generated gross proceeds of £184.0 million. The placing price of 3430 pence per share was a 8.0% discount to the closing mid market share price on 20 July 2022, being the date of the placing announcement.

Notes to the Consolidated Financial Statements

26. Share-based Payments

During the year, the Company operated the Unapproved Share Option Scheme, the Approved Share Option Scheme, the Save As You Earn (SAYE) Share Option Scheme, the Long Term Incentive Plan 2017 and the Global SAYE Plan 2018 as described below:

Unapproved and Approved Share Option Schemes

Under these Schemes, options are granted to certain Executives and employees of the Group (excluding Executive Directors) to purchase shares in the Company at a price fixed at the average market value over the three days prior to the date of grant. For the options to vest, there must be an increase in basic earnings per share of at least 12% above the growth in the UK Retail Prices Index (RPI) over a three year period. Once vested, options must be exercised within ten years of the date of grant.

Long Term Incentive Plan 2017

(a) Long Term Incentive Plan Awards

Vesting is dependent on two performance conditions which must be satisfied over a three year performance period commencing from the start of the financial year within which the award is granted. One third of each award is subject to a performance condition based on the Company's TSR performance over the performance period relative to an appropriate comparator over the performance period. Two thirds of each award is subject to a performance condition based on the growth in the Group's underlying diluted EPS over the performance period. Both the TSR element and the EPS element are subject to an additional ROCE underpin. Unless the Group's ROCE is 10% or more in the final year of the performance period, the awards will lapse in full regardless of TSR and EPS performance. For the purposes of this note they are detailed under the heading Long Term Incentive Plan.

(b) Qualifying LTIP Awards

In addition, awards can be structured as Qualifying LTIP Awards, consisting of a Company Share Option Plan (CSOP) option and a nil-cost LTIP award, with the ordinary award scaled back at exercise to take account of any gain made on exercise of the CSOP option. The Qualifying LTIP Awards are granted to the UK Senior Executive Team which includes the UK resident Executive Directors. The performance conditions are the same as those attached to the awards granted under Approved Share Option Schemes and Long Term Incentive Plan 2017. For the purposes of this note they are detailed under the heading Long Term Incentive Plan (Qualifying LTIP Awards).

(c) Market Value Options

Market value options may be granted under the Long Term Incentive Plan 2017 as tax-advantaged CSOP options and as Unapproved share options. These options are granted to certain Executives and employees of the Group (excluding Executive Directors) to purchase shares in the Company at a price fixed at the average market value over the three days prior to the date of grant. For the options to vest, there must be an increase in underlying diluted earnings per share of at least 12% above the growth in the UK Retail Prices Index (RPI) over a three year period. Once vested, options must be exercised within ten years of the date of grant. For the purposes of this note they are detailed under the headings Unapproved and Approved Share Option Schemes.

SAYE Option Scheme

This scheme is open to all UK employees. Participants save a fixed amount of up to £500 per month for either three or five years and are then able to use these savings to buy shares in the Company at a price fixed at a 20% discount to the market value at the start of the savings period. The SAYE options must ordinarily be exercised within six months of the completion of the relevant savings period. The exercise of these options is not subject to any performance criteria.

Global SAYE Plan 2018

The Global SAYE Plan 2018 is an international share option plan, with two schedules, one of which is a UK SAYE Scheme and the other operates as a qualifying Employee Stock Purchase Plan for the benefit of employees in the USA. This scheme is currently open to employees in 18 countries. Participants save a fixed amount of up to £500 (or the USD equivalent) per month for either three years (UK scheme) or two years (USA Scheme). The employees are then able to use these savings to buy shares in the Company at a price fixed at a 10% discount to the market value at the start of the savings period. The SAYE options must ordinarily be exercised within six months of the completion of the relevant savings period. For USA employees, there is a 12 month holding period that applies. The exercise of these options is not subject to any performance criteria.

Deferred Bonus Plan

The Dechra 2021 Deferred Bonus Plan (the 2021 DBP) is a discretionary share plan under which the deferred part of any bonus may be delivered. Any current or former employee is eligible to participate in the 2021 DBP at the discretion of the Board.

26. Share-based Payments continued

Year ended 30 June 2023

	Exercise Period	Exercise price per share Pence	At 1 July 2022 Number	Exercised Number	Granted Number	Lapsed Number	At 30 June 2023 Number
Unapproved Share Option Scheme							
11 September 2014†	2017-2024	763.00	2,000	–	–	–	2,000
15 September 2015†	2018-2025	975.00	2,500	–	–	–	2,500
19 September 2016†	2019-2026	1369.00	12,200	(2,000)	–	–	10,200
2 March 2018†	2020-2028	2506.00	45,107	(11,896)	–	–	33,211
26 October 2018†	2021-2028	2166.00	71,937	(17,115)	–	(2,000)	52,822
6 September 2019†	2022-2029	2964.00	115,419	(14,711)	–	(12,109)	88,599
22 September 2020	2023-2030	3237.00	134,066	–	–	(5,367)	128,699
16 September 2021	2024-2031	4909.00	167,138	–	–	(7,167)	159,971
9 September 2022	2025-2032	3199.00	–	–	187,174	(2,000)	185,174
			550,367	(45,722)	187,174	(28,643)	663,176
Approved Share Option Scheme							
19 September 2016†	2019-2026	1369.00	2,000	(2,000)	–	–	–
2 March 2018†	2021-2028	2506.00	1,696	(104)	–	–	1,592
26 October 2018†	2021-2028	2166.00	2,063	(1,385)	–	–	678
6 September 2019†	2022-2029	2964.00	7,272	(871)	–	–	6,401
22 September 2020	2023-2030	3237.00	7,236	–	–	(412)	6,824
16 September 2021	2024-2031	4909.00	4,888	–	–	–	4,888
9 September 2022	2025-2032	3199.00	–	–	5,826	–	5,826
			25,155	(4,360)	5,826	(412)	26,209
Long Term Incentive Plan							
6 September 2019	2022-2029	–	83,312	(54,562)	–	(28,750)	–
22 September 2020	2023-2030	–	43,388	–	–	–	43,388
16 September 2021	2024-2031	–	43,043	–	–	–	43,043
9 September 2022	2025-2032	–	–	–	84,277	–	84,277
			169,743	(54,562)	84,277	(28,750)	170,708
Long Term Incentive Plan (Qualifying LTIP Awards)							
22 September 2020	2023-2030	3237.00	3,201	–	–	–	3,201
22 September 2020	2023-2030	–	41,772	–	–	–	41,772
16 September 2021	2024-2031	4909.00	1,461	–	–	–	1,461
16 September 2021	2024-2031	–	16,567	–	–	–	16,567
9 September 2022	2025-2032	3199.00	–	–	1,368	–	1,368
9 September 2022	2025-2032	–	–	–	20,240	–	20,240
			63,001	–	21,608	–	84,609
SAYE Option Scheme							
12 October 2017	2020-2023	1646.00	4,224	(4,224)	–	–	–
29 November 2018	2021-2024	1974.00	4,158	(973)	–	–	3,185
			8,382	(5,197)	–	–	3,185
Global SAYE Plan 2018							
4 October 2019	2022-2023	2573.00	22,702	(20,929)	–	(1,773)	–
19 October 2020	2023-2024	2868.00	36,182	–	–	(5,790)	30,392
19 October 2020	2022-2023	2868.00	5,360	–	–	(5,360)	–
13 October 2021	2024-2025	4493.00	71,653	–	–	(55,053)	16,600
13 October 2021	2023-2024	4493.00	7,759	–	–	(2,856)	4,903
12 October 2022	2025-2026	2762.00	–	–	164,083	(5,862)	158,221
12 October 2022	2025-2026	2762.00	–	–	18,511	(364)	18,147
			143,656	(20,929)	182,594	(77,058)	228,263
Total			960,304	(130,770)	481,479	(134,863)	1,176,150
Weighted average exercise price			2638.28p	1411.09p	2300.14p	3082.87p	2605.24p

† Total share options exercisable at 30 June 2023 were 198,003.

Notes to the Consolidated Financial Statements

26. Share-based Payments continued

Year ended 30 June 2022

	Exercise Period	Exercise price per share Pence	At 1 July 2021 Number	Exercised Number	Granted Number	Lapsed Number	At 30 June 2022 Number
Unapproved Share Option Scheme							
11 September 2014†	2017–2024	763.00	2,000	–	–	–	2,000
15 September 2015†	2018–2025	975.00	2,500	–	–	–	2,500
19 September 2016†	2019–2026	1369.00	19,200	(7,000)	–	–	12,200
2 March 2018†	2020–2028	2506.00	63,360	(18,253)	–	–	45,107
26 October 2018†	2021–2028	2166.00	108,508	(35,737)	–	(834)	71,937
6 September 2019	2022–2029	2964.00	124,253	–	–	(8,834)	115,419
22 September 2020	2023–2030	3237.00	146,318	–	–	(12,252)	134,066
16 September 2021	2024–2031	4909.00	–	–	181,001	(13,863)	167,138
			466,139	(60,990)	181,001	(35,783)	550,367
Approved Share Option Scheme							
19 September 2016†	2019–2026	1369.00	2,000	–	–	–	2,000
2 March 2018†	2021–2028	2506.00	4,907	(3,107)	–	(104)	1,696
26 October 2018†	2021–2028	2166.00	2,906	(234)	–	(609)	2,063
6 September 2019	2022–2029	2964.00	7,413	–	–	(141)	7,272
22 September 2020	2023–2030	3237.00	7,236	–	–	–	7,236
16 September 2021	2024–2031	4909.00	–	–	5,499	(611)	4,888
			24,462	(3,341)	5,499	(1,465)	25,155
Long Term Incentive Plan							
26 October 2018	2021–2028	–	98,679	(72,820)	–	(25,859)	–
6 September 2019	2022–2029	–	84,184	–	–	(872)	83,312
22 September 2020	2023–2030	–	45,440	–	–	(2,052)	43,388
16 September 2021	2024–2031	–	–	–	43,043	–	43,043
			228,303	(72,820)	43,043	(28,783)	169,743
Long Term Incentive Plan (Qualifying LTIP Awards)							
22 September 2020	2023–2030	3237.00	3,309	–	–	(108)	3,201
22 September 2020	2023–2030	–	42,562	–	–	(790)	41,772
16 September 2021	2024–2031	4909.00	–	–	1,811	(350)	1,461
16 September 2021	2024–2031	–	–	–	17,505	(938)	16,567
			45,871	–	19,316	(2,186)	63,001
SAYE Option Scheme							
13 October 2016	2019–2022	1095.00	3,831	(3,813)	–	(18)	–
12 October 2017	2020–2023	1646.00	4,224	–	–	–	4,224
29 November 2018	2021–2024	1974.00	25,051	(20,619)	–	(274)	4,158
			33,106	(24,432)	–	(292)	8,382
Global SAYE Plan 2018							
4 October 2019	2022–2023	2573.00	23,938	(118)	–	(1,118)	22,702
16 October 2019	2021–2022	2517.00	15,823	(15,341)	–	(482)	–
19 October 2020	2023–2024	2868.00	39,183	(372)	–	(2,629)	36,182
19 October 2020	2022–2023	2868.00	6,091	–	–	(731)	5,360
13 October 2021	2024–2025	4493.00	–	–	76,212	(4,559)	71,653
13 October 2021	2023–2024	4493.00	–	–	8,236	(477)	7,759
			85,035	(15,831)	84,448	(9,996)	143,656
Total			882,916	(177,414)	333,307	(78,505)	960,304
Weighted average exercise price			1853.10p	1277.88p	3911.84p	2289.13p	2638.28p

† Total share options exercisable at 30 June 2022 were 139,503.

26. Share-based Payments continued

The weighted average exercise price of options eligible to be exercised at 30 June 2023 was 2538.37 pence (2022: 2157.48 pence). For options exercised during the year, the weighted average market price at the date of exercise was 3186.84 pence (2022: 4716.85 pence). The weighted average remaining contractual life of options outstanding at the Consolidated Statement of Financial Position date was 5.1 years (2022: 5.0 years).

Outstanding options on all Long Term Incentive, Approved and Unapproved plans prior to 30 June 2020 were exercisable at 30 June 2023. 7,422 options issued under SAYE plans were exercisable at 30 June 2023 (2022: 973).

National Insurance contributions are payable by the Company in respect of some of the share-based payments. These contributions are payable on the date of exercise based on the intrinsic value of the share-based payments and are therefore treated as cash settled awards. The Group had an accrual at 30 June 2023 of £0.9million (2022: £0.9 million), of which £0.6 million (2022: £0.3 million) related to vested options. The total charge to the Consolidated Income Statement within administrative expenses in respect of share-based payments was:

	2023 £m	2022 £m
Equity settled share-based transactions	2.4	3.3
Cash settled share-based transactions	(0.1)	(0.4)
	2.3	2.9

27. Changes in Net Debt

	At 1 July 2022 £m	Cash flows £m	New lease liabilities £m	Foreign exchange movements £m	Other non-cash movements £m	At 30 June 2023 £m
Liabilities from financing activities						
Lease liabilities within one year	(3.3)	4.8	(1.8)	0.2	(3.8)	(3.9)
Lease liabilities after one year	(12.1)	-	(3.9)	0.2	2.8	(13.0)
Bank loans after one year	(188.7)	(64.4)	-	16.1	(1.0)	(238.0)
Senior loan notes after one year	(125.0)	(126.2)	-	1.7	(0.1)	(249.6)
Sub-total	(329.1)	(185.8)	(5.7)	18.2	(2.1)	(504.5)
Other assets						
Cash and cash equivalents	120.9	(46.1)	-	(0.4)	-	74.4
Net debt	(208.2)	(231.9)	(5.7)	17.8	(2.1)	(430.1)

	At 1 July 2021 £m	Cash flows £m	New lease liabilities £m	Foreign exchange movements £m	Other non-cash movements £m	At 30 June 2022 £m
Liabilities from financing activities						
Lease liabilities within one year	(3.1)	4.1	(0.3)	(0.1)	(3.9)	(3.3)
Lease liabilities after one year	(12.8)	-	(3.5)	(0.6)	4.8	(12.1)
Bank loans after one year	(188.2)	-	-	(0.1)	(0.4)	(188.7)
Senior loan notes after one year	(114.5)	-	-	(10.4)	(0.1)	(125.0)
Sub-total	(318.6)	4.1	(5.6)	11.2	0.4	(329.1)
Other assets						
Cash and cash equivalents	118.4	(1.5)	-	4.0	-	120.9
Net debt	(200.2)	2.6	(3.8)	(7.2)	0.4	(208.2)

Notes to the Consolidated Financial Statements

28. Foreign Exchange Rates

The following primary exchange rates have been used in the translation of the results of foreign operations:

	Average rate for 2022	Closing rate at 30 June 2022	Average rate for 2023	Closing rate at 30 June 2023
Australian Dollar	1.8347	1.7594	1.7832	1.9106
Brazilian Real	6.9892	6.3189	6.2134	6.1504
Danish Krone	8.7826	8.6684	8.5616	8.6771
Euro	1.1807	1.1652	1.1504	1.1651
US Dollar	1.3316	1.2103	1.2038	1.2660

29. Acquisitions

Acquisition of Piedmont Animal Health Inc

On 25 July 2022, Dechra acquired 100% of the share capital of Piedmont Animal Health Inc, for a total consideration of £175.7 million (USD209.5 million). The fair value of the assets and liabilities acquired are now final.

	Fair value £m
Recognised amounts of identifiable assets and liabilities acquired	
Property, plant and equipment	0.3
Other receivables	0.3
Trade and other payables	(1.3)
Contingent consideration liabilities (note 30)	(4.6)
Cash	0.5
Intangible assets	173.4
Deferred tax liabilities	(35.7)
Net identifiable assets	132.9
Goodwill	42.8
Total consideration	175.7
Purchase consideration:	
Cash	175.7
Total purchase consideration	175.7
Net cash outflow arising on acquisition:	
Cash consideration	175.7
Less: Cash and cash equivalents	(0.5)
Net cash outflow arising on acquisition	175.2

29. Acquisitions continued**Acquisition of Piedmont Animal Health Inc continued**

The intangible assets, which relate to the intellectual property acquired, were valued based on a combination of both the excess earnings method and the replacement cost method. The approach adopted was dependent on the stage of the development of the intellectual property which relates to In-Process Research and Development assets. The table below shows on an indicative basis the sensitivity to reasonably possible changes in significant assumptions used in the valuation of the intangible assets. There would be a corresponding impact to the deferred tax liability (at the substantively enacted tax rate) and goodwill. The goodwill is not tax deductible.

	Intangible assets
1% increase in discount rates (£m)	(19.1)
1% decrease in discount rates (£m)	22.4
10% increase in cash flows (£m)	17.8
10% decrease in cash flows (£m)	(17.9)
10% increase in volume attrition upon patent expiry (£m)	(5.7)
10% decrease in volume attrition upon patent expiry (£m)	5.7
5% increase in ongoing volume attrition (£m)	(10.3)
5% decrease in ongoing volume attrition (£m)	20.2

The goodwill of £42.8m million arising from the acquisition has predominantly arisen due to the deferred tax on the intangible assets which was not considered when pricing the acquisition, given there is no intention to sell the vast majority of intangible assets. In addition goodwill also represents Piedmont's proven ability to develop new products, and therefore the ability to generate new opportunities. This is aligned with the market participation view of the acquisition.

Acquisition related costs (included in operating expenses) amounted to £0.2 million. Piedmont Animal Health Inc's results are reported within the Pharmaceuticals Research and Development Segment.

Piedmont Animal Health Inc contributed £nil revenue and £5.8 million loss to the Group's underlying operating profit for the period between the date of acquisition and the balance sheet date. If the acquisition had been completed on the first Day of the financial year, the contribution to the Group revenues for the Year would have been £nil and to the Group's underlying operating profit would have been a loss of £7.1 million. The reported operating loss after taking into account non-underlying items for acquisition and integration costs would be £7.3 million.

Notes to the Consolidated Financial Statements

29. Acquisitions continued

Acquisition of Med-Pharmex Holdings, Inc

On 26 August 2022, Dechra acquired 100% of the share capital of Med-Pharmex Holdings Inc., and its subsidiaries Med-Pharmex Property LLC, Med-Pharmex Inc and Cephazone Pharma LLC (collectively 'Med-Pharmex'). The Group paid £223.7 million (\$264.6 million) consideration. The fair value of the assets and liabilities acquired is now final.

	Fair value £m
Recognised amounts of identifiable assets and liabilities acquired	
Property, plant and equipment	47.9
Inventory	14.8
Trade and other receivables	6.9
Trade and other payables	(5.3)
Cash	2.6
Intangible assets	137.6
Current tax assets	1.3
Deferred tax liabilities	(38.0)
Net identifiable assets	167.8
Goodwill	55.9
Total consideration	223.7
Purchase consideration:	
Cash	223.7
Total purchase consideration	223.7
	£m
Net cash outflow arising on acquisition:	
Cash consideration	223.7
Less: Cash and cash equivalents	(2.6)
Net cash outflow arising on acquisition	221.1

The intangible assets, which relate to the intellectual property acquired principally relating to Developed Technology and In-Process Research and Development assets, were valued based on the excess earnings method. The table below shows on an indicative basis the sensitivity to reasonably possible changes in significant assumptions used in the valuation of the intangible asset. There would be a corresponding impact to the deferred tax liability (at the substantively enacted tax rate) and goodwill.

29. Acquisitions continued

	Intangible assets
1% increase in discount rates (£m)	(14.7)
1% decrease in discount rates (£m)	17.7
10% increase in cash flows (£m)	13.9
10% decrease in cash flows (£m)	(13.9)

The goodwill of £55.9 million arising from the acquisition has predominantly arisen due to the deferred tax on the intangible assets which was not considered when pricing the acquisition, given there is no intention to sell the vast majority of intangible assets. Goodwill also represents value stemming from future products developed, the acquired workforce, and strategic benefits from being able to transfer existing Dechra products into Med-Pharmex's under-utilised facilities, reducing external manufacturing costs and reliance on Contract Manufacturing Organisations. This is aligned with the market participation view of the acquisition. The goodwill is not tax deductible.

Inventory includes a fair value uplift of £3.3 million (USD4.0 million). A non-underlying charge of £3.3 million (USD4.0 million) relating to the fair value uplift on inventory that has been sold in the year has been taken to cost of sales in the income statement.

The gross contractual receivables amount to £6.2 million, which are expected to be fully recoverable.

Acquisition and related costs (included in operating expenses) amounted to £2.8 million. Med-Pharmex's results are reported within the NA Pharmaceuticals Segment.

Med-Pharmex contributed £28.9 million revenue and £0.5 million to the Group's underlying operating profit for the period between the date of acquisition and the balance sheet date. If the acquisition had been completed on the first Day of the financial year, the contribution to the Group revenues for the Year would have been £34.5 million and to the Group's underlying operating profit would have been £0.6 million. The reported operating loss after taking into account non-underlying items for the amortisation of intangible assets, fair value inventory adjustment and acquisition and integration costs would have been £10.6 million.

Notes to the Consolidated Financial Statements

30. Contingent Consideration

	2023 £m	2022 £m
Contingent consideration – less than one year	4.1	6.4
Contingent consideration – more than one year	71.6	104.0
	75.7	110.4

The consideration for certain acquisitions and licensing agreements includes amounts contingent on future events such as development milestones or sales performance. The Group has provided for the fair value of this contingent consideration as follows:

	Tri-Solfen* £m	Injectable Solution 1 £m	Mirataz £m	Laverdia* £m	Piedmont £m	Other £m	Total £m
As at 1 July 2021	56.2	1.6	14.4	–	–	8.0	80.2
Additions	–	–	–	57.9	–	2.7	60.6
Remeasurement through intangibles	(12.0)	–	(2.9)	(7.9)	–	(1.4)	(24.2)
Cash payments: investing activities	(14.6)	(0.8)	(0.7)	–	–	(3.6)	(19.7)
Finance expense	1.5	0.1	0.4	1.2	–	0.2	3.4
Foreign exchange adjustments	1.5	0.2	1.8	6.3	–	0.3	10.1
At 30 June 2022	32.6	1.1	13.0	57.5	–	6.2	110.4
Additions	–	–	–	–	–	0.8	0.8
Group acquisitions	–	–	–	–	4.6	–	4.6
Remeasurement through intangibles	(13.6)	–	(4.9)	(28.2)	(0.7)	(2.2)	(49.6)
Remeasurement through income statement	(0.9)	–	–	–	–	(0.3)	(1.2)
Cash payments: investing activities	(2.2)	(0.6)	(1.7)	(0.1)	–	(1.5)	(6.1)
Finance expense	8.7	0.1	2.6	7.3	0.6	1.5	20.8
Foreign exchange adjustments	(1.9)	–	(0.4)	(1.2)	(0.4)	(0.1)	(4.0)
At 30 June 2023	22.7	0.6	8.6	35.3	4.1	4.4	75.7

The table below shows on an indicative basis the sensitivity to reasonably possible changes in key inputs to the valuations of the contingent consideration liabilities. There would be a corresponding opposite impact on the intangible asset.

	Tri-Solfen*	Injectable Solution 1	Mirataz	Laverdia*	Piedmont	Other
Increase/(decrease) in financial liability						
10% increase in royalty forecasts £m	1.8	N/A	0.8	1.2	0.3	0.2
10% decrease in royalty forecasts £m	(1.8)	N/A	(0.9)	(1.2)	(0.3)	(0.2)
1% increase in discount rates £m	(1.3)	–	(0.3)	(1.6)	(0.4)	(0.1)
1% decrease in discount rates £m	1.4	–	0.3	1.7	0.1	0.1
5% appreciation in Sterling £m	(1.1)	–	(0.4)	(1.7)	(0.2)	(0.2)
5% depreciation in Sterling £m	1.2	–	0.5	1.9	0.2	0.2
Discount rate range in 2023 financial year	6.5%–21.0%	12.7%	10.1%–10.8%	6.5%–18.8%	6.7%–10.0%	11.0%–23.5%
Discount rate range in 2022 financial year	5.2%–25.0%	11.6%	7.3%–9.4%	5.1%–14.6%	N/A	10.2%–27.1%
Aggregate undiscounted cash outflow in relation to royalties (remaining term of royalty agreement)						
2023 £m (years)	39.5 (13.0)	N/A	13.6 (7.5)	23.3 (9.0)	7.2 (15.0)	0.9 (4.0)
2022 £m (years)	50.4 (14.0)	N/A	19.8 (8.5)	51.3 (10.0)	N/A	4.6 (5.0)

30. Contingent Consideration continued

The consideration payable for Tri-Solfen® is expected to be payable over a number of years, and relates to development milestones and sales performance royalties. During the year, the development milestones and sales performance royalties have been remeasured. At 30 June 2023, the liability was discounted between 6.5% and 21.0%. The broad range of discount rates in respect of this licensing agreement reflects the commercial makeup of the arrangement, with discount rates for milestone payments related to regulatory approvals being lower and based on a cost of debt approach and those with more variability in timing and quantum of future cash flows being higher and based on a Capital Asset Pricing Model based approach, also taking into account systematic risk associated with elements of the future cash flows. The gross value of the development milestones is AUD11.0 million.

The consideration payable for Laverdia® is expected to be payable over a number of years, and relates to approval milestones and sales performance royalties. During the Period, approval milestones and sales performance royalties have been remeasured. At 30 June 2023, the liability was discounted between 6.5% and 18.8% reflecting the commercial makeup of the arrangement similar to Tri-Solfen®. The gross value of the approval and sales performance (non-royalty) milestones is USD40.5 million.

The consideration for products acquired under Piedmont Animal Health Inc is expected to be payable over fifteen years, and relates to approval milestones and sales performance royalties under pre-existing licensing arrangements.

The consideration for Mirataz® relates to sales performance and is expected to be payable over a number of years. The consideration remaining for a licensing agreement for an injectable solution relates to development milestones.

31. Related Party Transactions

Subsidiaries

The Group's ultimate Parent Company is Dechra Pharmaceuticals PLC. A list of subsidiaries is shown within the financial statements of the Company on pages 244 to 246.

Transactions with Key Management Personnel

The details of the remuneration, Long Term Incentive Plans, shareholdings, share options and pension entitlements of individual Directors are included in the Directors' Remuneration Report on pages 152 to 163. The remuneration of key management is disclosed in note 8.

Associates

The Group holds a 49.5% stake in Medical Ethics Pty Ltd, which is the holding company of Animal Ethics Pty Ltd. In 2017 the Group entered into a licensing agreement with Animal Ethics Pty Ltd for Tri-Solfen® for which the fair value of associated contingent consideration is disclosed in note 30. During the year AUD2.0 million (£1.1 million) of approval milestones has been paid.

In 2021, the Group entered into a licensing agreement with Animal Ethics Pty Ltd for the marketing authorisations of Tri-Solfen® in Australia and New Zealand. An associated royalty payment of AUD2.0 million (£1.1 million) has also been paid in the Year.

32. Off Balance Sheet Arrangements

The Group has no off balance sheet arrangements to disclose as required by S410A of the Companies Act 2006.

33. Contingent Liabilities

The Group continues to monitor developments in relation to EU State Aid investigations. On 25 April 2019, the EU Commission's final decision regarding its investigation into the UK's Controlled Foreign Company (CFC) regime was published. It concluded that the legislation up until December 2018 does partially represent State Aid. This decision was upheld by the EU General Court on 8 June 2022, when it dismissed the UK Government's annulment application. The UK Government has since lodged an appeal to the EU Court of Justice in August 2022.

At 30 June 2023, the Group considers that the potential amount of additional tax payable is between £nil and £2.75 million (2022: £nil and £4.0 million) depending on the basis of calculation and the outcome of HMRC's appeal to the EU Court of Justice. Based on current advice, the Group does not consider any provision is required in relation to this investigation. This judgement is based on current interpretation of legislation and professional advice.

The Group received charging notices from HMRC in January and February 2021 under The Taxation (Post Transition Period) Act for the full exposure (£2.75 million) and has paid this to HMRC. As the Group considers that HMRC's appeal will be successful, the charging notices which were settled in full during 2021 (£2.75 million) are recorded as current tax receivables on the basis that the amount will be repaid in due course.

At 30 June 2023, contingent liabilities arising in the normal course of business amounted to £7.1 million (2022: £12.4 million) relating to licence and distribution agreements. The stage of development of the projects underpinning the agreements dictates that a commercially stable product is yet to be achieved, and accordingly an intangible asset and a contingent consideration liability have not been recognised.

Notes to the Consolidated Financial Statements

34. Subsequent Events

On 20 July 2023, the shareholders voted in favour of the proposed cash offer for the Company by Freya Bidco Limited. The pending acquisition of the Company is conditional upon respective antitrust approvals or the expiry of the applicable waiting periods in the relevant jurisdictions.

35. Underlying Operating Profit, EBITDA, ROCE and Profit Before Taxation Reconciliation

	2023 £m	2022 £m
Operating profit		
Underlying operating profit/EBIT is calculated as follows:		
Operating profit	6.3	95.5
Non-underlying operating expenses (note 5)	158.8	78.8
Underlying operating profit/EBIT	165.1	174.3
Depreciation	13.7	11.1
Amortisation and impairment	4.9	5.2
Underlying earnings before interest, tax, depreciation and amortisation (EBITDA)	183.7	190.6
Profit before taxation		
Underlying profit before taxation is calculated as follows:		
(Loss)/profit before taxation	(36.1)	77.6
Non-underlying operating expenses	158.8	78.8
Amortisation of notional acquired intangibles from equity accounting for associates	0.8	0.7
Share of realised non-underlying profit of investments accounted for using the equity method	(0.9)	(0.6)
Loss on extinguishment of debt	0.6	-
Foreign exchange (gains)/ losses on contingent consideration	(3.7)	10.1
Unwind of discount associated with contingent consideration	20.8	3.4
Underlying profit before taxation	140.3	170.0
Return on capital employed		
	2023 £m	2022 £m
Net assets	755.2	666.8
Adjusted for:		
Net debt	430.1	208.2
Net corporate tax liability/(asset) (note 20)	(2.8)	1.2
Net deferred tax liability (note 15)	71.4	33.5
Closing operating assets	1,253.9	909.7
Opening operating assets	909.7	878.9
Average operating assets	1,081.8	894.3
	2023 £m	2022 £m
Underlying operating profit	165.1	174.3
Average operating assets	1,081.8	894.3
Return on capital employed	15.3%	19.5%

Company Statement of Financial Position

At 30 June 2023

	Note	2023 £m	2022 £m
Fixed assets			
Intangible assets	v	4.3	6.2
Tangible assets	vi	2.0	1.6
Investments	iv	920.1	735.7
		926.4	743.5
Current assets			
Trade and other receivables (includes amounts falling due after more than one year of £364.8 million (2022: £51.1million))	vii	446.4	115.0
Cash at bank and in hand	viii	49.6	85.8
		496.0	200.8
Borrowings	x	(0.3)	(0.2)
Trade and other payables	ix	(134.1)	(147.3)
Net current assets		361.6	53.3
Total assets less current liabilities		1,288.0	796.8
Non-current liabilities			
Borrowings	x	(468.2)	(150.2)
Net assets		819.8	646.6
Equity			
Called up share capital	xii	1.1	1.1
Share premium account		596.0	413.9
Foreign currency translation reserve		0.6	0.6
Merger reserve		82.6	82.6
At 1 July		148.4	153.2
Profit for the year attributable to the owners		37.8	37.1
Other changes in retained earnings		(46.7)	(41.9)
Retained earnings		139.5	148.4
Total shareholders' funds		819.8	646.6

The financial statements were approved by the Board of Directors on 12 October 2023 and were signed on its behalf by:

Ian Page

Chief Executive Officer
12 October 2023

Paul Sandland

Chief Financial Officer
12 October 2023

Company number: 3369634

Company Statement of Changes in Shareholders' Equity

For the year ended 30 June 2023

	Called up share capital £m	Share premium account £m	Foreign currency translation reserve £m	Merger reserve £m	Retained earnings £m	Total shareholders' funds £m
Year ended 30 June 2022						
At 1 July 2021	1.1	411.6	0.6	82.6	153.2	649.1
Profit for the year	-	-	-	-	37.1	37.1
Total comprehensive income	-	-	-	-	37.1	37.1
Transactions with owners						
Dividends paid	-	-	-	-	(44.8)	(44.8)
Share-based payment charge	-	-	-	-	2.9	2.9
Shares issued	-	2.3	-	-	-	2.3
Total contributions by and distributions to owners	-	2.3	-	-	(41.9)	(39.6)
At 30 June 2022	1.1	413.9	0.6	82.6	148.4	646.6
Year ended 30 June 2023						
At 1 July 2022	1.1	413.9	0.6	82.6	148.4	646.6
Profit for the year	-	-	-	-	37.8	37.8
Other comprehensive income	-	-	-	-	2.8	2.8
Total comprehensive income	-	-	-	-	40.6	40.6
Transactions with owners						
Dividends paid	-	-	-	-	(51.7)	(51.7)
Share-based payment charge	-	-	-	-	2.2	2.2
Shares issued	-	182.1	-	-	-	182.1
Total contributions by and distributions to owners	-	182.1	-	-	(49.5)	132.6
At 30 June 2023	1.1	596.0	0.6	82.6	139.5	819.8

Refer to the Group notes for dividend paid (note 10), share-based payment charge (note 26) and shares issued (note 25).

Merger Reserve

The merger reserve represents the excess of fair value over nominal value of shares issued in consideration for the acquisition of subsidiaries where statutory merger relief has been applied in the financial statements of the Company.

Notes to the Company Financial Statements

(i) Principal Accounting Policies of the Company

Accounting Principles

The separate financial statements of the Company have been prepared on a going concern basis, under the historical cost convention, in accordance with applicable UK accounting standards and the Companies Act 2006.

Basis of Preparation

The Directors opted to prepare the financial statements for the year ended 30 June 2023 in accordance with FRS 101 'Reduced Disclosure Framework' and the Companies Act 2006. The principal accounting policies applied in the preparation of these financial statements are set out below, and have been applied consistently.

No income statement is presented for the Company as permitted by Section 408(2) and (3) of the Companies Act 2006. The profit within the accounts of the Company was £40.6 million (2022: £37.1 million). The going concern of the Company is wholly interdependent on the going concern basis of the Group, which is considered in Note 1(b).

The following exemptions have been taken in preparing the financial statements:

- a. The requirements of paragraphs 45(b) and 46 to 52 of IFRS 2 'Share-based Payment', exempting the Company from preparing share based payment disclosures.
- b. The requirements of IFRS 7 'Financial Instruments: Disclosures'
- c. The following requirements of IAS 1:
 - Paragraphs 10(d) and 111, exempting the Company from providing a cash flow statement and information;
 - Paragraph 16, exempting the Company from providing a statement of compliance with all IFRSs;
 - Paragraph 38A, exempting the Company from the requirement for a minimum of two of each primary statement and the related notes;
 - Paragraph 38B to D, exempting the Company from the requirement to present additional comparative information; and
 - Paragraphs 134 to 136, exempting the Company from presenting Capital Management disclosures.
- d. The requirements of IAS 7 'Statement of Cash Flows', exempting the company from preparing a cash flow statement.
- e. The requirements of paragraph 17 of IAS 24 'Related Party Disclosures', exempting the Company from disclosing details of all key management compensation.
- f. The requirements in IAS 24 'Related Party Disclosures' to disclose related party transactions with wholly-owned members of the Group.
- g. The requirements of paragraphs 30 and 31 of IAS 8 'Accounting Policies, Changes in Accounting Estimates and Errors' exempting the Company from disclosing the impact of new accounting standards that have been issued but are not yet effective.

There are no significant estimates or judgements.

Adoption of New and Revised Standards

A number of amendments to IFRSs became effective for the financial year beginning on 1 July 2022. The Company has applied the amendments to IAS1, Practice Statement 2, IAS8 and IAS12 (deferred tax related to assets and liabilities arising from a single transaction and International tax reform pillar 2 model rules). None of these amendments had any impact on the Company's accounting policies and did not require retrospective adjustments.

Investments

Investments held as fixed assets are stated at cost less any impairment losses. Where the consideration for the acquisition of a subsidiary undertaking includes shares in the Company to which the provisions of section 612 of the Companies Act 2006 apply, cost represents the nominal value of the shares issued together with the fair value of any additional consideration given and costs. Where investments are denominated in foreign currencies, they are treated as monetary assets and revalued at each year end date.

Notes to the Company

Financial Statements

(i) Principal Accounting Policies of the Company continued

Intangible Assets

Intangible assets are stated at cost less accumulated amortisation and impairment losses. Amortisation is charged to the income statement on a straight line basis over the estimated useful economic life of the asset. The estimated useful lives are:

- product rights 10 to 15 years
- software 5 to 7 years

Tangible Assets

Tangible assets are stated at cost less accumulated depreciation and impairment losses. Depreciation is charged to the income statement on a straight line basis over the estimated useful economic life of the asset. The estimated useful lives are:

- short leasehold buildings period of lease
- motor vehicles 4 years
- plant and fixtures 3 to 15 years

Dividends

Dividends are recognised in the year in which they are approved by the Company's shareholders or, in the case of an interim dividend, when the dividend is paid. Dividends receivable from subsidiaries are recognised when either received in cash or applied to reduce a creditor balance with the subsidiary.

Interest-Bearing Borrowings

Interest-bearing borrowings are recognised initially at fair value less attributable transaction costs. Subsequent to initial recognition, interest-bearing borrowings are stated at amortised cost with any difference between cost and redemption value being recognised in the income statement over the period of the borrowings on an effective interest basis.

Employee Benefits

(a) Pensions

The Company operates a Group stakeholder personal pension scheme for certain employees. Obligations for contributions are recognised as an expense in the income statement as incurred.

(b) Share-based Payment Transactions

The Company operates a number of equity settled share-based payment programmes that allow employees to acquire shares of the Company. The Company also operates Long Term Incentive Plans for Directors and Senior Executives.

The fair value of shares or options granted is recognised as an employee expense on a straight-line basis in the income statement with a corresponding movement in equity. The fair value is measured at grant date and spread over the period during which the employees become unconditionally entitled to the shares or options (the vesting period). The fair value of the shares or options granted is measured using a valuation model, taking into account the terms and conditions upon which the shares or options were granted. The amount recognised as an expense in the income statement is adjusted to take into account an estimate of the number of shares or options that are expected to vest together with an adjustment to reflect the number of shares or options that actually do vest except where forfeiture is only due to market-based conditions not being achieved.

The fair values of grants under the Long Term Incentive Plan have been determined using the Monte Carlo simulation model. The fair values of options granted under all other share option schemes have been determined using the Black-Scholes option pricing model.

National Insurance contributions payable by the Company on the intrinsic value of share-based payments at the date of exercise are treated as cash settled awards and revalued to market price at each statement of financial position date. Where the Company grants options over its own shares to the employees of its subsidiaries, it recharges the expense to those subsidiaries.

Foreign Currency

Foreign currency transactions are translated into Sterling using the exchange rates prevailing at the dates of the transactions. Monetary assets and liabilities are translated at the closing rate at the reporting date. Foreign exchange gains and losses are recognised in the income statement.

(i) Principal Accounting Policies of the Company continued**Taxation**

The income tax expense or credit for the year is the tax payable on the current year's taxable income, based on the applicable income tax rate for the UK, adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses. The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period. Deferred tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Deferred tax is determined using tax rates (and laws) that have been enacted or substantively enacted by the end of the reporting period and are expected to apply when the related deferred tax asset is realised or the deferred tax liability is settled. Deferred tax assets are recognised only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses. Current and deferred tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Financial Guarantee Contracts

Where the Company enters into financial guarantee contracts to guarantee the indebtedness of other companies within its Group, the Company considers these to be insurance arrangements, and accounts for them as such. In this respect, the Company treats the guarantee contract as a contingent liability until such time as it becomes probable that the Company will be required to make a payment under the guarantee.

Amounts Owed by Subsidiary Undertakings

Amounts owed by subsidiary undertakings are initially recognised at fair value and subsequently measured at this value less loss allowances, calculated using the three stage IFRS 9 model.

(ii) Directors and Employees

Total emoluments of Directors (including pension contributions) amounted to £1.9 million (2022: £3.9 million).

Information relating to Directors' emoluments, share options and pension entitlements is set out in the Directors' Remuneration Report on pages 152 to 163. Tony Griffin's remuneration is paid by Eurovet Animal Health B.V. in Euros but reported in Sterling for the purposes of these figures. The exchange rate used was 1.1504 (2022: 1.1807).

	2023 Number	2022 Number
Administration	86	71
Total	86	71

The costs incurred in respect of these employees were:

	2023 £m	2022 £m
Wages and salaries	7.0	7.9
Social security costs	1.0	1.5
Other pension costs	0.5	0.4
Share-based payments charge (see note 26)	2.3	2.9
Total	10.8	12.7

The Group operates a stakeholder personal pension scheme for certain employees and contributed between 3% and 12% of pensionable salaries. Total pension contributions amounted to £0.5 million (2022: £0.4 million).

(iii) Profit Before Taxation

The following items have been included in arriving at profit before taxation of continuing operations:

	2023 £m	2022 £m
Depreciation of property, plant and equipment		
– owned assets	0.1	0.1
– right-of-use assets	0.3	0.2
Amortisation of intangible assets	2.3	2.6
Auditors' remuneration – audit of these financial statements	0.1	0.1

Notes to the Company Financial Statements

(iv) Investments

	Shares in subsidiary undertakings £m
Cost	
At 1 July 2022	867.0
Additions	203.3
At 30 June 2023	1,070.3
Impairment	
At 1 July 2022	131.3
Impairment	18.9
At 30 June 2023	150.2
Net book value	
At 30 June 2023	920.1
At 1 July 2022	735.7

On 25 July 2022, the Company invested £176.0 million into the share capital of Dechra Investments Limited, a wholly owned subsidiary. On 1 March 2023, the Company invested £24.5 million into the share capital of Dechra Holdings Netherlands B.V., a wholly owned subsidiary as part of a wider restructuring of the Group. On 16 February 2023, Dechra Finance Sterling Limited (DFS Limited) distributed its 14% stake in Dechra Finance Limited (DF Limited) to the Company, taking the Company's total shareholding in DF Limited to 100%. The addition to investments of £2.8m has been treated as a return on capital and measured at fair value. A list of subsidiary undertakings is given in note (xiii).

Impairment

Investments in subsidiaries are assessed annually to determine if there is any indication that these may be impaired. In March 2023, DF Limited reduced its share capital by EUR 18.3 million (£15.8 million) and paid a dividend equivalent to the amount of the capital reduction to the Company. In addition, as a result of the unwinding of an internal group financing arrangement, certain loan receivables and payables of an equal amount were settled and going forward DF Limited's future net interest cash inflows will be less. As a consequence the Company's investment in this entity was tested for impairment.

The recoverable amount of the investment was determined based on a value-in-use calculation. The recoverable amount calculated in respect of DF Limited was £3.9m, which was £18.9 million lower than the carrying value of the investment and therefore an impairment loss of this amount has been recognised. The calculation of value-in-use uses contractual cash flow projections based on financial budgets approved by management covering an appropriate period. Given the nature of this entity, this period was considered to be the term of the financing loans. A post-tax discount rate of 8.88% was used to calculate the recoverable amount. There is no material difference in the approach taken to using pre-tax cash flows and a pre-tax rate compared to post-tax cash flows and a post-tax rate, as required by IAS 36. No reasonable change in the discount rate used would result in a material change to the impairment recognised. Following DFS Limited's distribution of its 14% stake in DF Limited, the Company's investment in DFS Limited was considered for impairment and no impairment was identified.

(v) Intangible Assets

	Product rights £m	Software £m	Total intangible assets £m
Cost			
At 1 July 2022	5.1	14.3	19.4
Additions	–	0.4	0.4
At 30 June 2023	5.1	14.7	19.8
Accumulated Amortisation			
At 1 July 2022	5.1	8.1	13.2
Charge for the year	–	2.3	2.3
At 30 June 2023	5.1	10.4	15.5
Net book value			
At 30 June 2023	–	4.3	4.3
At 30 June 2022	–	6.2	6.2

(vi) Tangible Assets

	Short leasehold buildings £m	Motor vehicles £m	Plant and fixtures £m	Total £m
Cost				
At 1 July 2022	1.6	0.4	0.9	2.9
Additions	0.4	0.4	–	0.8
Disposals	–	(0.2)	–	(0.2)
At 30 June 2023	2.0	0.6	0.9	3.5
Accumulated Depreciation				
At 1 July 2022	0.4	0.2	0.7	1.3
Charge for the year	0.2	0.1	0.1	0.4
Disposals	–	(0.2)	–	(0.2)
At 30 June 2023	0.6	0.1	0.8	1.5
Net book value				
At 30 June 2023	1.4	0.5	0.1	2.0
At 30 June 2022	1.2	0.2	0.2	1.6
Net book value of right-of-use assets				
At 30 June 2023	1.4	0.5	–	1.9
At 30 June 2022	1.2	0.2	–	1.4
Depreciation charge of right-of-use assets				
2023	0.2	0.1	–	0.3
2022	0.1	0.1	–	0.2

Included in additions are £0.8 million (2022: £0.5 million) of right-of-use assets.

(vii) Trade and Other Receivables

	2023 £m	2022 £m
Amounts owed by subsidiary undertakings	433.2	107.8
Group relief receivable	4.0	4.1
Deferred taxation (see note (xi))	1.5	0.8
Other receivables	6.4	1.2
Prepayments and accrued income	1.3	1.1
	446.4	115.0

Included in debtors are amounts of £1.5 million (2022: £0.8 million) due after more than one year relating to deferred tax assets.

Of the amounts owed by subsidiary undertakings, £363.9 million is due after more than one year (2022: £50.3 million). This is made up of a balance of £2.8 million repayable in 2026 (interest of 1.50% above Mexican National Bank Base Rate), £1.8 million repayable in 2027 (interest of 3.5% above Canadian Dollar offered rate), £205.3 million repayable in 2030 (interest between 5.00 – 5.35%), and a balance of £154.0 million repayable in 2032 (interest of 2.25%). The remaining amounts owed by subsidiary undertakings of £69.3 million are unsecured and repayable on demand. Of the £69.3 million, £57.1 million attracts interest of between 0.976% and 1.98% above Risk Free Reference rate, with the remaining trade balance of £12.2 million being interest free. The provision for impairment against amounts owed by subsidiary undertakings is £4.1 million and have been calculated based on a six month period where repayable on demand, and on a twelve month period for the remainder. Amounts owed by subsidiary undertakings are considered to have low credit risk.

(viii) Cash at Bank and in Hand

	2023 £m	2022 £m
Cash at bank and in hand	49.6	85.8
	49.6	85.8

Notes to the Company Financial Statements

(ix) Trade and Other Payables

	2023 £m	2022 £m
Trade payables	1.8	1.0
Other payables	0.1	0.1
Amounts due to subsidiary undertakings	122.9	139.7
Accruals and deferred income	9.3	6.5
	134.1	147.3

Amounts due to subsidiary undertakings are primarily unsecured and repayable on demand. £84.0 million attracts interest between 0.026% and 0.25% below Risk Free Reference rate; the remaining balance is interest free.

In accordance with IAS 10 'Events after the Balance Sheet Date', the proposed final dividend for the year ended 30 June 2023 is nil per share (2022: 32.89 pence per share).

(x) Borrowings

	2023 £m	2022 £m
Borrowings due within one year		
Lease liabilities	0.3	0.2
Borrowings due after more than one year		
Aggregate bank loan, senior loan notes and lease liabilities instalments repayable:		
– between one and two years	0.3	0.1
– between two and five years	263.8	68.3
– over five years	208.5	83.3
Arrangement fees netted off	(4.4)	(1.5)
	468.2	150.2
Total borrowings	468.5	150.4

On 31 March 2023, the Company entered into a new multi-currency Revolving Credit Facility Agreement ("RCF") in the maximum amount of £340.0 million and maturing 31 March 2028. This RCF is provided by a syndicate of banks comprising BNP Paribas, CaixaBank SA UK branch, Crédit Industriel et Commercial, London Branch, Handelsbanken Capital Markets, Handelsbanken plc, HSBC UK Bank plc, PNC Capital Markets LLC, Santander UK plc and The Governor and Company of the Bank of Ireland. The covenant requirements in the RCF remain unchanged from the prior Revolving Credit Facility Agreement (being Interest Cover in respect of any Relevant Period shall not be less than 4:1 and Leverage in respect of any Relevant Period shall not exceed 3:1).

The RCF uses Risk Free Reference (RFR) rates, with the relevant RFR rates for the principal Borrowings of the Company being SONIA (for Borrowings in GBP), SOFR (for Borrowings in USD) and EURIBOR (for Borrowings in EUR). The interest rate charged on any new Borrowings drawn under the RCF will be the relevant RFR rate plus the Margin. The Margin on the RCF is a minimum of 1.40% and a maximum of 2.30%, dependent upon the Leverage (the ratio of Adjusted Net Debt to Adjusted underlying EBITDA) of the Group. At 30 June 2023, £220.4 million was drawn against the £340.0 million RCF. The facility is not secured on any specific assets of the Group but is supported by a joint and several cross guarantee structure. All covenants were met during the year ended 30 June 2023.

In January 2020 the Company undertook a Private Placement raising EUR50.0 million and USD100.0 million (under seven and ten year new senior secured notes respectively) which remains fully drawn at 30 June 2023 amounting to £121.9 million. The Private Placement amounts are not secured on any specific assets of the Group, but are supported by a joint and several guarantee structure. Interest is charged on the EUR50.0 million amount at a fixed rate of 1.19% until maturity (January 2027). Interest is charged on the USD100.0 million amount at a fixed rate of 3.34% until maturity (January 2030).

On 14 July 2022 the Group undertook a further Private Placement raising EUR50.0 million and EUR100.0 million (under seven and ten year new senior secured notes respectively), the proceeds of which were used to repay existing debt. Both facilities remain fully drawn at 30 June 2023 amounting to £128.7 million. Interest is charged on the EUR50.0 million senior secured notes at a fixed rate of 3.64% until maturity (July 2029), and on the EUR100.0 million senior secured notes at a fixed rate of 3.93% until maturity (July 2032).

No interest has been capitalised during the year (2022: £nil).

The Company guarantees certain borrowings of other Group companies under the above facilities, which at 30 June 2023 amounted to £21.0 million (2022: £164.7 million).

(xi) Deferred Tax

	£m
At 1 July 2022 (included in trade and other receivables)	0.8
Recognised in the income statement	0.7
At 30 June 2023 (included in trade and other receivables)	1.5

Deferred tax has been calculated using the rate of 25.0% based on the timing of when each individual deferred tax balance is expected to reverse in the future as follows (2022: 19.0% or 25.0%):

	2023 £m	2022 £m
Short term timing differences	0.9	1.0
Losses	0.4	–
Accelerated capital allowances	0.2	(0.2)
	1.5	0.8

Deferred tax assets in relation to losses amounting to £nil (2022: £nil) have not been recognised due to uncertainty over their recoverability.

(xii) Called Up Share Capital

	Ordinary shares of 1 pence each			
	2023		2022	
	£m	Number	£m	Number
Allotted, called up and fully paid at start of year	1.1	108,392,737	1.1	108,215,323
New shares issued	–	5,495,453	–	177,414
Allotted, called up and fully paid at end of year	1.1	113,888,190	1.1	108,392,737

Details of new ordinary shares issued following the exercise of options under the Long Term Incentive Plan and the Approved, Unapproved and SAYE Share Option Schemes are shown in notes 25 and 26 to the Consolidated Financial Statements.

The Company issued 5,247,813 shares of 1 pence each by way of a placing and 116,870 ordinary shares via a retail offer, both at an issue price of 3430 pence per share on 25 July 2022. The placing generated gross proceeds of £184.0 million. The placing price of 3430 pence per share was a 8.0% discount to the closing mid market share price on 20 July 2022, being the date of the placing announcement.

Share Options

Details of outstanding share options over ordinary shares of 1 pence at 30 June 2023 under the various Group share option schemes are shown in note 26 to the Consolidated Financial Statements.

Notes to the Company Financial Statements

(xiii) Subsidiary Undertakings

Operating Subsidiaries

Name	Country of Incorporation	Principal Activity	Registered Address	Shareholder
Ampharmco, LLC *	USA	Manufacturer of veterinary pharmaceuticals	1401 Joel East Road, Fort Worth, TX76140-6003, United States	Dechra Holdings US Inc
AST Farma B.V. *	The Netherlands	Marketer of veterinary pharmaceuticals and distributor of veterinary pharmaceuticals and equipment	Wilgenweg 7, 3421TV Oudewater, The Netherlands	Dechra Finance B.V.
Cephazone Pharma LLC*	USA	Developer, regulatory and manufacturer of veterinary pharmaceuticals	Principal Place of Business: 7015 College Blvd, Suite 510, Overland Park KS 66211, United States	Med-Pharmex Inc.
Dechra Brasil Produtos Veterinarios LTDA *	Brazil	Developer, regulatory, manufacturer and marketer of veterinary pharmaceuticals	Travessa Dalva de Oliveira, 237, Industrias Leves, Londrina, Parana 86030-370, Brazil	AST Farma B.V.
Dechra Development LLC *	USA	Contract regulatory and product development services for the Group	Principal Place of Business: 7015 College Blvd, Suite 510, Overland Park KS 66211, United States	Dechra Holdings US Inc
Dechra Limited *	England and Wales	Developer, regulatory, product development, manufacturer and marketer of veterinary pharmaceuticals	Snaygill Industrial Estate, Keighley Road, Skipton, BD23 2RW, United Kingdom	Dechra Investments Limited
Dechra Finance Australia Limited *	England and Wales	Financial services	24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, CW9 7UA, United Kingdom	Dechra Limited
Dechra Finance B.V. *	The Netherlands	Financial services and Holding Company	Pettelaarpark 38, 5216PD 's-Hertogenbosch, The Netherlands	Dechra Holdings Netherlands B.V.
Dechra Finance Ireland Designated Activity Company *	Republic of Ireland	Financial services	6th Floor, 2 Grand Canal Square, Dublin 2, Ireland	Dechra Limited
Dechra Finance Limited	England and Wales	Financial services	24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, CW9 7UA, United Kingdom	Dechra Pharmaceuticals PLC
Dechra Finance Sterling Limited	England and Wales	Financial services	24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, CW9 7UA, United Kingdom	Dechra Pharmaceuticals PLC
Dechra Productos Veterinarios, S.A. de C.V. *	Mexico	Developer, regulatory and marketer of veterinary pharmaceuticals	Campus Corporativo Coyoacán, Avenida Coyoacán, número 1622, Colonia Del Valle, C.P. 03100 Delegación Benito Juárez, Ciudad de México, México	Dechra Limited
Dechra Regulatory B.V. *	The Netherlands	Regulatory	Handelsweg 25, 5531AE Bladel, The Netherlands	Dechra Holdings Netherlands B.V.
Dechra Veterinary Products (Australia) Pty Limited *	Australia	Developer, regulatory, manufacturer and marketer of veterinary pharmaceuticals	2 Cal Close, Somersby NSW 2250, Australia	Dechra Holding Australia Pty Limited
Dechra Veterinary Products GmbH *	Austria	Marketer of veterinary pharmaceuticals and pet diets	Hintere Achmehlerstrasse 1a, 6850 Dornbirn, Austria	Dechra Limited
Dechra Veterinary Products N.V. *	Belgium	Marketer of veterinary pharmaceuticals and pet diets	Achterstenhoek 48, 2275 Lille, Belgium	Eurovet Animal Health B.V.
Dechra Veterinary Products, Inc *	Canada	Marketer of veterinary pharmaceuticals and pet diets	100 King Street West, Suite 6100, 1 First Canadian Place, Toronto ON M5X 1B8, Canada	Dechra Limited
Dechra Veterinary Products A/S	Denmark	Marketer of veterinary pharmaceuticals and pet diets	Mekuvej 9, DK-7171 Uldum, Denmark	Dechra Pharmaceuticals PLC
Dechra Veterinary Products Limited *	England and Wales	Marketer of veterinary pharmaceuticals and pet diets	24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, CW9 7UA, United Kingdom	Dechra Veterinary Products A/S
Dechra Veterinary Products Oy *	Finland	Marketer of veterinary pharmaceuticals and pet diets	Linnoitustie 4, 02600 Espoo, Finland	Dechra Veterinary Products A/S

(xiii) Subsidiary Undertakings continued**Operating Subsidiaries**

Name	Country of Incorporation	Principal Activity	Registered Address	Shareholder
Dechra Veterinary Products SAS *	France	Marketer of veterinary pharmaceuticals and pet diets	60 Avenue du Centre, 78180 Montigny le Bretonneux, France	Dechra Veterinary Products A/S
Dechra Veterinary Products Deutschland GmbH*	Germany	Marketer of veterinary pharmaceuticals and distributor of veterinary pharmaceuticals and equipment	Hauptstr. 6-8, 88326, Aulendorf, Germany	Eurovet Animal Health B.V.
Dechra Veterinary Products S.r.l. *	Italy	Marketer of veterinary pharmaceuticals and pet diets	Via Agostino da Montefeltro 2, 10134 Torino, Italy	Dechra Limited
Dechra Veterinary Products B.V. *	The Netherlands	Marketer of veterinary pharmaceuticals and pet diets	Wilgenweg 7, 3421TV Oudewater, The Netherlands	Dechra Veterinary Products A/S
Dechra Veterinary Products NZ Limited *	New Zealand	Marketer of veterinary pharmaceuticals and distributor of veterinary pharmaceuticals and equipment	Level 11, 41 Shortland Street, Auckland, 1010, New Zealand	Dechra Holding Australia Pty Limited
Dechra Veterinary Products AS *	Norway	Marketer of veterinary pharmaceuticals and pet diets	Henrik Ibsens Gate 90, Postboks 2943 Solli, 0230 Oslo, Norway	Dechra Veterinary Products A/S
Dechra Veterinary Products Sp. z o.o. *	Poland	Marketer of veterinary pharmaceuticals and pet diets	1st Floor, 61 Moldlinska Str., 03-199 Warsaw, Poland	Dechra Limited
Dechra Veterinary Products, S.L. Unipersonal *	Spain	Marketer of veterinary pharmaceuticals and pet diets	C Tunset, Num. 20, Planta 6, Barcelona, 08006, Spain	Dechra Veterinary Products A/S
Dechra Veterinary Products AB *	Sweden	Marketer of veterinary pharmaceuticals and pet diets	Stora Wäsby Orangeriet 3, Upplands Väsby, 194 37, Sweden	Dechra Veterinary Products A/S
Dechra Veterinary Products, LLC *	USA	Marketer and manufacturer of veterinary pharmaceuticals and pet diets	Principal Place of Business: 7015 College Blvd, Suite 525, Overland Park KS 66211, United States	Dechra Holdings US Inc
Dechra Veterinary Products Korea Yuhan Hoesa *	Korea	Marketer of veterinary pharmaceuticals and pet diets	4, 5th floor, Royal Building, 19, Saemunan-ro 5-gil, Jongno-gu, Seoul, Korea	Dechra Limited
Eurovet Animal Health B.V. *	The Netherlands	Holding Company, developer, regulatory and manufacturer of veterinary pharmaceuticals	Handelsweg 25, 5531AE Bladel, The Netherlands	Dechra Holdings Netherlands B.V.
Genera d.d. *	Croatia	Holding Company, developer, regulatory, manufacturer and marketer of veterinary pharmaceuticals and crop protection	Svetonedeljska cesta 2, Kalinovica, 10436 Rakov Potok, Croatia	Eurovet Animal Health B.V.
Genera d.o.o. Sarajevo *	Bosnia and Herzegovina	Marketer of veterinary pharmaceuticals	Trg međunarodnog prijateljstva 10, 71000 Sarajevo, Bosnia and Herzegovina	Genera d.d.
Genera Pharma d.o.o. *	Serbia	Marketer of veterinary pharmaceuticals	Gostivarska 70, Vozdovac, 11000 Beograd, Serbia	Genera d.d.
Genera SI d.o.o. *	Slovenia	Marketer of veterinary pharmaceuticals	Parmova Ulica, Ljubljana, Slovenia	Genera d.d.
Le Vet. B.V. *	The Netherlands	Marketer of veterinary pharmaceuticals	Wilgenweg 7, 3421TV Oudewater, The Netherlands	Le Vet Beheer B.V.
Med-Pharmex, Inc *	USA	Developer, regulatory and manufacturer of veterinary pharmaceuticals	Principal Place of Business: 7015 College Blvd, Suite 510, Overland Park KS 66211, United States	Med-Pharmex Holdings, Inc
Med-Pharmex Property LLC *	USA	Property Company	Principal Place of Business: 7015 College Blvd, Suite 510, Overland Park KS 66211, United States	Med-Pharmex Holdings, Inc

All the above related undertakings are 100% owned by the Company. For those marked with *, these are indirectly owned through other related undertakings within the list.

Notes to the Company Financial Statements

(xiii) Subsidiary Undertakings continued

Other subsidiaries

Name	Country of Incorporation	Principal Activity	Registered Address	Shareholder
Arnolds Veterinary Products Limited *	England and Wales	Non-trading	24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, CW9 7UA, United Kingdom	Veneto Limited
Black Griffin Holdings, LLC *	USA	Holding Company	1401 Joel East Road, Fort Worth TX 76140-6003, United States	Dechra Holdings US Inc
Broomco 4263 Limited *	England and Wales	Non-trading	24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, CW9 7UA, United Kingdom	Veneto Limited
Dales Pharmaceuticals Limited *	England and Wales	Non-trading	24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, CW9 7UA, United Kingdom	Veneto Limited
Dechra Holding Australia Pty Limited *	Australia	Holding Company	2 Cal Close, Somersby NSW 2250, Australia	Dechra Limited
Dechra Holdings Netherlands B.V.	The Netherlands	Holding Company	Pettelaarpark 38, 5216PD 's-Hertogenbosch, Netherlands	Dechra Pharmaceuticals PLC
Dechra Holdings US Inc *	USA	Holding Company	Principal Place of Business: 7015 College Blvd, Suite 525, Overland Park KS 66211, United States	Dechra Limited
Dechra Investments Limited	England and Wales	Holding Company	24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, CW9 7UA, United Kingdom	Dechra Pharmaceuticals PLC
Dechra Veterinary Products Suisse GmbH *	Switzerland	Holding Company	Messeplatz 10, CH-4058, Basel, Switzerland	Dechra Limited
DermaPet, Inc *	USA	Non-trading	Principal Place of Business: 7015 College Blvd, Suite 525, Overland Park KS 66211, United States	Dechra Veterinary Products LLC
Dragon Fire Holdings, LLC *	USA	Holding Company	1401 Joel East Road, Fort Worth TX 76140-6003, United States	Dechra Holdings US Inc
Farvet Laboratories B.V. *	The Netherlands	Non-trading	Handelsweg 25, 5531AE Bladel, The Netherlands	Eurovet Animal Health B.V.
Le Vet. Beheer B.V. *	The Netherlands	Holding Company	Wilgenweg 7, 3421TV Oudewater, The Netherlands	Dechra Finance B.V.
Med-Pharmex Holdings, Inc *	USA	Holding Company	Principal Place of Business: 7015 College Blvd, Suite 525, Overland Park KS 66211, United States	Dechra Holdings US Inc
Piedmont Animal Health Inc *	USA	Non-trading	Principal Place of Business: 7015 College Blvd, Suite 510, Overland Park KS 66211, United States	Dechra Veterinary Products LLC
Veneto Limited	England and Wales	Holding Company	24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, CW9 7UA, United Kingdom	Dechra Pharmaceuticals PLC

All the above related undertakings are 100% owned by the Company. For those marked with *, these are indirectly owned through other related undertakings within the list.

(xiv) Subsequent Events

On 20 July 2023, the shareholders voted in favour of the proposed cash offer for the Company by Freya Bidco Limited. The pending acquisition of the Company is conditional upon respective antitrust approvals or the expiry of the applicable waiting periods in the relevant jurisdictions.

Financial History

	2023 £m	2022 £m	2021 £m	2020 £m	2019 £m
Consolidated Income Statement					
Revenue	761.5	681.8	608.0	515.1	481.8
Underlying operating profit	165.1	174.3	162.2	128.3	127.4
Underlying profit after taxation	107.9	131.7	117.6	95.4	92.5
Underlying earnings per share					
– basic (pence)	95.09	121.57	108.77	92.50	90.24
– diluted (pence)	94.57	120.84	108.14	92.19	90.01
Dividend per share (pence)	12.50	44.89	40.50	34.29	31.60
Operating profit	6.3	95.5	84.0	52.2	39.0
(Loss)/profit after taxation	(27.9)	58.2	55.5	33.9	30.9
Earnings per share					
– basic (pence)	(24.59)	53.72	51.33	32.87	30.15
– diluted (pence)	(24.59)	53.40	51.03	32.76	30.07
Consolidated Statement of Financial Position					
Non-current assets	1,101.5	848.9	821.9	788.7	750.0
Current assets	467.9	444.4	392.2	448.9	291.5
Current liabilities	(164.0)	(158.7)	(155.8)	(137.3)	(118.1)
Non-current liabilities	(650.2)	(467.8)	(425.4)	(462.8)	(414.3)
Shareholders' funds	755.2	666.8	632.9	637.5	509.1
Consolidated Statement of Cash Flows					
Net cash inflow from operating activities	63.6	122.9	89.1	106.4	81.8
Net cash outflow from investing activities	(426.2)	(78.3)	(136.1)	(81.5)	(61.9)
Net cash (outflow)/inflow from financing activities	316.5	(46.1)	(55.1)	118.9	(20.1)